0000355019-21-000009.txt : 20210216 0000355019-21-000009.hdr.sgml : 20210216 20210216150339 ACCESSION NUMBER: 0000355019-21-000009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FONAR CORP CENTRAL INDEX KEY: 0000355019 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112464137 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-10248 FILM NUMBER: 21636746 BUSINESS ADDRESS: STREET 1: 110 MARCUS DR CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 6316942929 MAIL ADDRESS: STREET 1: 110 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 10-Q 1 fonar_10q-final.htm FONAR CORPORATION 10-Q ENDED DECEMBER 31, 2020

FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended DECEMBER 31, 2020

Commission file number 0-10248

FONAR CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE		11-2464137
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
110 Marcus Drive Melville, New York		11747
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (631) 694-2929

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES _X_ NO ___

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit such files. YES _X_ NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of accelerated filer, large accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):Large accelerated filer___ Accelerated filer ___ Non-accelerated filer _X__ Smaller reporting company _X_ Emerging growth company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ___ NO _X_

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the close of the latest practicable date.

Class		Outstanding at February 5, 2021
Common Stock, par value $.0001		6,554,210
Class B Common Stock, par value $.0001		146
Class C Common Stock, par value $.0001		382,513
Class A Preferred Stock, par value $.0001		313,438

FONAR CORPORATION AND SUBSIDIARIES

INDEX

PART I - FINANCIAL INFORMATION		PAGE
Item 1. Financial Statements
Condensed Consolidated Balance Sheets - December 31, 2020 (Unaudited) and June 30, 2020		3
Condensed Consolidated Statements of Income for the Three Months Ended December 31, 2020 and December 31, 2019 (Unaudited)		6
Condensed Consolidated Statements of Income for the Six Months Ended December 31, 2020 and December 31, 2019 (Unaudited)		7
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended December 31, 2020 and December 31, 2019 (Unaudited)		8
Condensed Consolidated Statements of Changes in Equity for the Six Months Ended December 31, 2020 and December 31, 2019 (Unaudited)		9
Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2020 and December 30, 2019 (Unaudited)		10
Notes to Condensed Consolidated Financial Statements (Unaudited)		11
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		26
Item 3. Quantitative and Qualitative Disclosures About Market Risk		33
Item 4. Controls and Procedures		34
PART II - OTHER INFORMATION		34
Item 1. Legal Proceedings		34
Item 1A. Risk Factors		34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		36
Item 3. Defaults Upon Senior Securities		36
Item 4. Mine Safety Disclosures		36
Item 5. Other Information		36
Item 6. Exhibits		36
Signatures		37

Page 2

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

ASSETS

	December 31, 2020		June 30, 2020 *
Current Assets:
Cash and cash equivalents	$	40,579	$	36,802
Short term investments		32		32
Accounts receivable – net		4,171		4,313
Accounts receivable - related party		72		6
Medical receivable – net		16,373		16,172
Management and other fees receivable – net		29,808		27,438
Management and other fees receivable – related medical practices – net		7,262		6,896
Inventories		1,844		1,649
Costs and estimated earnings in excess of billings on uncompleted contracts		153		153
Income tax receivable		—		671
Prepaid expenses and other current assets		1,302		1,758
Total Current Assets		101,596		95,890

Accounts receivable		2,594		2,730
Deferred income tax asset		16,848		18,810
Property and equipment – net		21,683		21,364
Right-of-use Asset – operating lease		29,570		31,392
Right-of-use Asset – financing lease		1,226		1,326
Goodwill		3,985		3,985
Other intangible assets – net		4,014		4,109
Other assets		632		653
Total Assets	$	182,148	$	180,259

*Condensed from audited financial statements.

See accompanying notes to condensed consolidated financial statements.

Page 3

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

LIABILITIES AND STOCKHOLDERS’ EQUITY

	December 31, 2020		June 30, 2020 *
Current Liabilities:
Current portion of long-term debt and capital leases	$	222	$	108
Accounts payable		2,198		1,965
Other current liabilities		5,584		8,185
Unearned revenue on service contracts		4,029		4,105
Unearned revenue on service contracts – related party		55		—
Operating lease liability - current portion		3,403		3,370
Financing lease liability - current portion		200		75
Customer deposits		1,232		855

Total Current Liabilities		16,923		18,663

Long-Term Liabilities:
Unearned revenue on service contracts		2,528		2,656
Deferred income tax liability		234		234
Due to related medical practices		93		93
Operating lease liability – net of current portion		28,415		30,105
Financing lease liability – net of current portion		1,151		1,251
Long-term debt and capital leases, less current portion		780		865
Other liabilities		148		150

Total Long-Term Liabilities		33,349		35,354
Total Liabilities		50,272		54,017

*Condensed from audited financial statements.

See accompanying notes to condensed consolidated financial statements.

Page 4

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

LIABILITIES AND STOCKHOLDERS’ EQUITY (Continued)

STOCKHOLDERS' EQUITY:	December 31, 2020			June 30, 2020 *
Class A non-voting preferred stock $.0001 par value; 453 shares authorized at December 31, 2020 and June 30, 2020, 313 issued and outstanding at December 31, 2020 and June 30, 2020	$	—		$	—
Preferred stock $.001 par value; 567 shares authorized at December 31, 2020 and June 30, 2020, issued and outstanding – none		—			—
Common Stock $.0001 par value; 8,500 shares authorized at December 31, 2020 and June 30, 2020, 6,566 and 6,459 issued at December 31, 2020 and June 30, 2020, 6,554 and 6,447 outstanding at December 31, 2020and June 30, 2020		1			1
Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at December 31, 2020 and June 30, 2020; .146 issued and outstanding at December 31, 2020 and June 30, 2020		—			—
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at December 31, 2020 and June 30, 2020, 383 issued and outstanding at December 31, 2020 and June 30, 2020		—			—
Paid-in capital in excess of par value		185,101			183,076
Accumulated deficit		(50,596	)		(56,215	)
Treasury stock, at cost - 12 shares of common stock at December 31, 2020 and June 30, 2020		(675	)		(675	)
Total Fonar Corporation’s Stockholders’ Equity		133,831			126,187
Noncontrolling interests		(1,955	)		55
Total Stockholders' Equity		131,876			126,242
Total Liabilities and Stockholders' Equity	$	182,148		$	180,259

*Condensed from audited financial statements.

See accompanying notes to condensed consolidated financial statements.

Page 5

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

	FOR THE THREE MONTHS ENDED DECEMBER 31,
REVENUES	2020			2019
Patient fee revenue – net of contractual allowances and discounts	$	5,238		$	5,996
Product sales – net		3			3
Service and repair fees – net		1,862			2,038
Service and repair fees - related parties – net		28			28
Management and other fees – net		11,340			10,996
Management and other fees - related medical practices – net		2,693			2,390
Total Revenues – Net		21,164			21,451
COSTS AND EXPENSES
Costs related to patient fee revenue		2,649			2,958
Costs related to product sales		192			120
Costs related to service and repair fees		608			772
Costs related to service and repair fees - related parties		9			10
Costs related to management and other fees		6,237			6,203
Costs related to management and other fees – related medical practices		1,522			1,621
Research and development		424			583
Selling, general and administrative		4,541			4,163
Total Costs and Expenses		16,182			16,430
Income From Operations		4,982			5,021
Interest Expense		(16	)		(19	)
Investment Income		75			139
Income Before Provision for Income Taxes and Noncontrolling Interests		5,041			5,141
Provision for Income Taxes		(1,113	)		(932	)
Net Income		3,928			4,209
Net Income - Noncontrolling Interests		(817	)		(1,105	)
Net Income – Attributable to FONAR	$	3,111		$	3,104
Net Income Available to Common Stockholders	$	2,923		$	2,914
Net Income Available to Class A Non-Voting Preferred Stockholders	$	140		$	142
Net Income Available to Class C Common Stockholders	$	48		$	48
Basic Net Income Per Common Share Available to Common Stockholders	$	0.45		$	0.45
Diluted Net Income Per Common Share Available to Common Stockholders	$	0.44		$	0.44
Basic and Diluted Income Per Share – Class C Common	$	0.12		$	0.13
Weighted Average Basic Shares Outstanding – Common Stockholders		6,465			6,447
Weighted Average Diluted Shares Outstanding - Common Stockholders		6,593			6,575
Weighted Average Basic and Diluted Shares Outstanding – Class C Common		383			383

See accompanying notes to condensed consolidated financial statements.

Page 6

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

	FOR THE SIX MONTHS ENDED DECEMBER 31,
REVENUES	2020			2019
Patient fee revenue – net of contractual allowances and discounts	$	10,330		$	12,041
Product sales – net		31			195
Service and repair fees – net		3,788			4,102
Service and repair fees - related parties – net		55			55
Management and other fees – net		22,554			22,024
Management and other fees - related medical practices – net		5,386			4,780
Total Revenues – Net		42,144			43,197
COSTS AND EXPENSES
Costs related to patient fee revenue		5,169			5,820
Costs related to product sales		325			450
Costs related to service and repair fees		1,234			1,522
Costs related to service and repair fees - related parties		18			20
Costs related to management and other fees		11,788			12,208
Costs related to management and other fees – related medical practices		2,950			3,157
Research and development		824			1,055
Selling, general and administrative		10,704			8,458
Total Costs and Expenses		33,012			32,690
Income From Operations		9,132			10,507
Other Expenses		(140	)		—
Interest Expense		(38	)		(40	)
Investment Income		187			287
Income Before Provision for Income Taxes and Noncontrolling Interests		9,141			10,754
Provision for Income Taxes		(1,962	)		(2,039	)
Net Income		7,179			8,715
Net Income - Noncontrolling Interests		(1,560	)		(2,313	)
Net Income – Attributable to FONAR	$	5,619		$	6,402
Net Income Available to Common Stockholders	$	5,281		$	6,010
Net Income Available to Class A Non-Voting Preferred Stockholders	$	252		$	292
Net Income Available to Class C Common Stockholders	$	86		$	100
Basic Net Income Per Common Share Available to Common Stockholders	$	0.82		$	0.93
Diluted Net Income Per Common Share Available to Common Stockholders	$	0.80		$	0.92
Basic and Diluted Income Per Share – Class C Common	$	0.23		$	0.26
Weighted Average Basic Shares Outstanding – Common Stockholders		6,456			6,440
Weighted Average Diluted Shares Outstanding - Common Stockholders		6,584			6,568
Weighted Average Basic and Diluted Shares Outstanding – Class C Common		383			383

See accompanying notes to condensed consolidated financial statements.

Page 7

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

For the Three Months Ending December 31, 2020

	Common Stock		Paid in capital in excess of par value		Accumulated Deficit			Treasury Stock			Non Controlling Interests			Total
Balance - September 30, 2020	$	1	$	183,076	($	53,707	)	($	675	)	($	642	)	$	128,053
Issuance of Common Stock		—		2,025		—									2,025
Net income		—		—		3,111			—			—			3,111
Distributions - Non controlling		—		—		—			—			(2,130	)		(2,130	)
Income - Non controlling interests		—		—		—			—			817			817
Balance - December 31, 2020	$	1	$	185,101	($	50,596	)	($	675	)	($	1,955	)	$	131,876

For the Three Months Ending December 31, 2019

	Common Stock		Paid in capital in excess of par value		Accumulated Deficit			Treasury Stock			Non Controlling Interests			Total
Balance - September 30, 2019	$	1	$	183,076	($	61,157	)	($	675	)	$	1,609		$	122,854
Net income		—		—		3,104						—			3,104
Distributions - Non controlling		—		—		—			—			(1,980	)		(1,980	)
Income - Non controlling interests		—		—		—			—			1,105			1,105
Balance - December 31, 2019	$	1	$	183,076	($	58,053	)	($	675	)	$	734		$	125,083

Page 8

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

For the Six Months Ending December 31, 2020

	Common Stock		Paid in capital in excess of par value		Accumulated Deficit			Treasury Stock			Non Controlling Interests			Total
Balance - June 30, 2020	$	1	$	183,076	($	56,215	)	($	675	)	$	55		$	126,242
Issuance of Common Stock		—		2,025		—						—			2,025
Net income		—		—		5,619			—			—			5,619
Distributions - Non controlling		—		—		—			—			(3,570	)		(3,570	)
Income - Non controlling interests		—		—		—			—			1,560			1,560
Balance - December 31, 2020	$	1	$	185,101	($	50,596	)	($	675	)	($	1,955	)	$	131,876

For the Six Months Ending December 31, 2019

	Common Stock		Paid in capital in excess of par value		Accumulated Deficit			Treasury Stock			Non Controlling Interests			Total
Balance - June 30, 2019	$	1	$	181,086	($	64,455	)	($	675	)	$	2,156		$	118,113
Issuance of Common Stock		—		1,990		—						—			1,990
Net income		—		—		6,402			—			—			6,402
Distributions - Non controlling		—		—		—			—			(3,735	)		(3,735	)
Income - Non controlling interests		—		—		—			—			2,313			2,313
Balance - December 31, 2019	$	1	$	183,076	($	58,053	)	($	675	)	$	734		$	125,083

Page 9

FONAR CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

	FOR THE SIX MONTHS ENDED DECEMBER 31,
	2020			2019
Cash Flows from Operating Activities:
Net income	$	7,179		$	8,715
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,009			2,003
Amortization on right-of-use assets		1,922			1,656
Provision(Recovery) for bad debts		2,825			(978	)
Deferred income tax – net		1,962			1,816
Compensatory element of stock issuances		83			—
Stock issued for costs and expenses		1,941			1,990
Abandoned patents		1			—
(Increase) decrease in operating assets, net:
Accounts, medical and management fee receivable(s)		(5,549	)		(4,300	)
Notes receivable		25			11
Costs and estimated earnings in excess of billings on uncompleted contracts		—			372
Inventories		(195	)		47
Income tax receivable		671			—
Prepaid expenses and other current assets		452			330
Other assets		(1	)		(45	)
Increase (decrease) in operating liabilities, net:
Accounts payable		233			(576	)
Other current liabilities		(2,748	)		430
Operating lease liabilities		(1,657	)		(1,447	)
Financing lease liabilities		24			—
Customer deposits		378			28
Billings in excess of costs and estimated earnings on uncompleted contracts		—			12
Other liabilities		(3	)		123
Net cash provided by operating activities		9,552			10,187
Cash Flows from Investing Activities:
Purchases of property and equipment		(2,143	)		(4,656	)
Purchase of short term investment		—			(199	)
Cost of patents		(90	)		(62	)
Net cash used in investing activities		(2,233	)		(4,917	)
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations		(35	)		(24	)
Proceeds from debt		63			—
Distributions to noncontrolling interests		(3,570	)		(3,735	)
Net cash used in financing activities		(3,542	)		(3,759	)
Net Increase in Cash and Cash Equivalents		3,777			1,511
Cash and Cash Equivalents - Beginning of Period		36,802			13,882
Cash and Cash Equivalents - End of Period	$	40,579		$	15,393

See accompanying notes to condensed consolidated financial statements.

Page 10

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name “Health Management Company of America”.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on October 1, 2020 for the fiscal year ended June 30, 2020.

During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the volume has risen. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company immediately enacted wide scale furloughs, deferment of up to 50% of management salaries, halted variable compensation plans and rent deferrals we negotiated with the majority of all landlords. The Company also received some government stimulus funds from the Paycheck Protection Program (“PPP”) and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

Page 11

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenues

On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

Earnings Per Share

Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three and six months ended December 31, 2020 and 2019.

Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.

Page 12

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Earnings Per Share (Continued)

	Three months ended December 31, 2020						Three months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	3,111	$	2,923	$	48	$	3,104	$	2,914	$	48
Denominator:
Weighted average shares outstanding		6,465		6,465		383		6,447		6,447		383
Basic income per common share	$	0.48	$	0.45	$	0.12	$	0.48	$	0.45	$	0.13
Diluted
Denominator: Weighted average shares outstanding				6,465		383				6,447		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,593		383				6,575		383
Diluted income per common share			$	0.44	$	0.12			$	0.44	$	0.13

	Six months ended December 31, 2020						Six months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	5,619	$	5,281	$	86	$	6,402	$	6,010	$	100
Denominator:
Weighted average shares outstanding		6,456		6,456		383		6,440		6,440		383
Basic income per common share	$	0.87	$	0.82	$	0.23	$	0.99	$	0.93	$	0.26
Diluted
Denominator: Weighted average shares outstanding				6,456		383				6,440		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,584		383				6,568		383
Diluted income per common share			$	0.80	$	0.23			$	0.92	$	0.26

Page 13

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are current evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of the adoption.

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.

Page 14

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE

Receivables, net is comprised of the following at December 31, 2020, and June 30, 2020:

	December 31, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,686	$	515	$	4,171
Accounts receivable - related party	$	72		—	$	72
Medical receivable	$	16,373	$	—	$	16,373
Management and other fees receivable	$	43,298	$	13,490	$	29,808
Management and other fees receivable from related medical practices ("PC’s")	$	10,982	$	3,720	$	7,262

	June 30, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,828	$	515	$	4,313
Accounts receivable - related party	$	6		—	$	6
Medical receivable	$	16,172	$	—	$	16,172
Management and other fees receivable	$	38,501	$	11,063	$	27,438
Management and other fees receivable from related medical practices ("PC’s")	$	10,218	$	3,322	$	6,896

The Company's customers are concentrated in the healthcare industry.

Accounts Receivable

Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.

Page 15

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Continued)

Long Term Accounts Receivable

The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years as of December 31, 2020 is as follows:

2022	$	853
2023		827
2024		752
2025		96
Total	$	2,528

Medical Receivables

Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.

Management and Other Fees Receivable

The Company's receivables from the related and non-related professional corporations (PC's) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC's of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.

Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66% and 60% of the PCs’ net revenues for the three months ended December 31, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. Approximately 66% and 63% of the PCs’ net revenue for the six months ended December 31, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management's expectations.

Page 16

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)

Management and Other Fees Receivable (Continued)

Net revenues from management and other fees charged to the related PCs accounted for approximately 12.7% and 11.1% of the consolidated net revenues for the three months ended December 31, 2020 and 2019, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately 12.8% and 11.1% of the consolidated net revenues for the six months ended December 31, 2020 and 2019, respectively.

Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.

The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2020 and 2019 are summarized in the following table.

	For the Three Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	966	$	1,335
Medicare/Medicaid		206		276
Workers' Compensation/Personal Injury		3,543		4,112
Other		523		273
Patient Fee Revenue, net of contractual allowances and discounts	$	5,238	$	5,996

	For the Six Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	1,912	$	2,689
Medicare/Medicaid		404		542
Workers' Compensation/Personal Injury		6,930		8,406
Other		1,084		404
Patient Fee Revenue, net of contractual allowances and discounts	$	10,330	$	12,041

Page 17

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 4 – OPERATING & FINANCING LEASES

During February 2016, FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance foOTr operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases.

The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Also included in other current assets is a $202 receivable from a landlord for tenant improvements. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2020 is as follows:

Year Ending December 31,		Operating Lease Payments			Financing Lease Payments
	2021	$	4,960		$	244
	2022		4,877			244
	2023		4,599			244
	2024		4,480			244
	2025		4,301			244
	Thereafter		17,505			287
	Present value discount		(8,904	)		(156	)
	Total lease liability	$	31,818		$	1,351

Page 18

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 5 - INVENTORIES

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Purchased parts, components and supplies	$	1,614	$	1,544
Work-in-process		230		105
Total Inventories	$	1,844	$	1,649

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

Information relating to uncompleted contracts is as follows:

	December 31, 2020		June 30, 2020
Costs incurred on uncompleted contracts	$	448	$	448
Estimated earnings		309		309
Subtotal		757		757
Less: Billings to date		604		604
Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	153	$	153

Page 19

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECMEBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 7 – OTHER INTANGIBLE ASSETS

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Capitalized software development costs	$	7,005	$	7,005
Patents and copyrights		5,171		5,082
Non-compete		4,100		4,100
Customer relationships		3,800		3,800
Gross Other intangible assets		20,076		19,987
Less: Accumulated amortization		16,062		15,878
Other Intangible Assets	$	4,014	$	4,109

Amortization of patents and copyrights for the three months ended December 31, 2020 and 2019 amounted to $44 and $47, respectively.

Amortization of non-compete for the three months ended December 31, 2020 and 2019 amounted to $0 and $147, respectively.

Amortization of customer relationships for the three months ended December 31, 2020 and 2019 amounted to $47 and $47, respectively.

Amortization of patents and copyrights for the six months ended December 31, 2020 and 2019 amounted to $89 and $94, respectively.

Amortization of non-compete for the six months ended December 31, 2020 and 2019 amounted to $0 and $293, respectively.

Amortization of customer relationships for the six months ended December 31, 2020 and 2019 amounted to $95 and $95, respectively.

Page 20

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 8 – OTHER CURRENT LIABILITIES

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Accrued salaries, commissions and payroll taxes	$	2,573	$	4,492
Litigation accruals		9		443
Sales tax payable		1,123		1,353
Legal and other professional fees		276		113
Accounting fees		180		120
Self-funded health insurance reserve		123		87
Accrued interest and penalty		511		877
Other		789		700
Other Current Liabilities	$	5,584	$	8,185

NOTE 9 – STOCKHOLDERS EQUITY

Common Stock

During the six months ended December 31, 2020, the Company issued 102 shares of common stock for costs and expenses of $1,941 and 4 shares of common stock to employees and consultants as compensation valued at $83.

During the six months ended December 31, 2019, the Company issued 90 shares of common stock for costs and expenses of $1,990.

NOTE 10 - SEGMENT AND RELATED INFORMATION

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.

Page 21

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 10 - SEGMENT AND RELATED INFORMATION (Continued)

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.

Summarized financial information concerning the Company's reportable segments is shown in the following table:

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the three months ended Dec. 31, 2020
Net revenues from external customers	$	1,893		$	19,271	$	21,164
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(8	)	$	4,990	$	4,982
Depreciation and amortization	$	65		$	977	$	1,042
Capital expenditures	$	70		$	1,728	$	1,798

For the three months ended Dec. 31, 2019
Net revenues from external customers	$	2,069		$	19,382	$	21,451
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(790	)	$	5,811	$	5,021
Depreciation and amortization	$	94		$	914	$	1,008
Capital expenditures	$	153		$	2,116	$	2,269

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the six months ended Dec. 31, 2020
Net revenues from external customers	$	3,874		$	38,270	$	42,144
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(569	)	$	9,701	$	9,132
Depreciation and amortization	$	132		$	1,878	$	2,010
Capital expenditures	$	90		$	2,143	$	2,233

For the six months ended Dec. 31, 2019
Net revenues from external customers	$	4,352		$	38,845	$	43,197
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(1,526	)	$	12,033	$	10,507
Depreciation and amortization	$	185		$	1,818	$	2,003
Capital expenditures	$	1,754		$	2,964	$	4,718

Page 22

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 11 – SUPPLEMENTAL CASH FLOW INFORMATION

During the six months ended December 31, 2020 and December 31, 2019, the Company paid $35 and $14 for interest, respectively.

During the six months ended December 31, 2020 and December 31, 2019, the Company paid $145 and $228 for income taxes, respectively.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.

There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

Other Matters

The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of December 31, 2020, the Company has recorded tax obligations of approximately $1.1 million plus interest and penalties of approximately $466. The Company is in the process of determining the regulatory requirements in order to become compliant.

The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $110 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2020 and June 30, 2020, the Company had approximately $123 and $87, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets.

The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.

Page 23

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 13 - INCOME TAXES

In accordance with ASC 740-270, Income Taxes – Interim Reporting, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the six months ended December 31, 2020 and 2019, the Company recorded income tax expense of $1,962 in 2020 as compared to $2,039 in 2019. The 2020 provision is comprised of a current income tax component of $0 and a deferred income tax component of $1,962. Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.

ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits.

In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses.

The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016.

The Company recorded a deferred tax asset of $16,848 and a deferred tax liability of $234 as of December 31, 2020, primarily relating to net operating loss carryforwards of approximately $47,208 available to offset future taxable income through 2031. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes.

Page 24

FONAR CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Amounts and shares in thousands, except per share amounts)

(UNAUDITED)

NOTE 13 - INCOME TAXES (Continued)

At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.

As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities.

Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of December 31, 2020, no such changes in ownership have occurred.

The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits.

A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.

NOTE 14 – SUBSEQUENT EVENTS

The Company has evaluated events that occurred subsequent to December 31, 2020 and through the date the condensed consolidated financial statements were issued.

Page 25

FONAR CORPORATION AND SUBSIDIARIES

Item 2. – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

For the six month period ended December 31, 2020, we reported a net income of $7.2 million on revenues of $42.1 million as compared to net income of $8.7 million on revenues of $43.2 million for the six month period ended December 31, 2019. Operating income decreased from $10.5 million for the six month period ended December 31, 2019 to $9.1 million for the six month period ended December 31, 2020.

For the three month period ended December 31, 2020, we reported a net income of $3.9 on revenues of $21.2 as compared to net income of $4.2 million on revenues of $21.5 million for the three month period ended December 31, 2019.

The revenue decreased, from $43.2 million for the first six months of fiscal 2020 to $42.1 million for the first six months of fiscal 2021, was primarily due to a decrease in patient fee revenue of $1.7 million, from $12.0 million for the first six months of fiscal 2020 to $10.3 million for the first six months of fiscal 2021. Revenues from product sales and service and repair fees decreased by 11.1% from $4.4 million for the first six months of fiscal 2020 to $3.9 million for the first six months of fiscal 2021.

While our revenues decreased, our costs and expenses increased, resulting in our operating income decreasing to $9.1 million for the six months ended December 31, 2020 as compared to $10.5 million for the six months ended December 31, 2019. In terms of percentages, costs and expenses increased 1.0% from $32.7 million for the first six months of fiscal 2020 to $33.0 million for the first six months of fiscal 2021, while revenues decreased, from $43.2 million for the first six months of fiscal 2020 to $42.1 million for the first six months of fiscal 2021. The increase in costs and expenses was due to a $2.2 million increase in selling, general and administrative expenses, from $8.5 million to $10.7 million, consisting largely of increases in reserves for management fees.

Fonar’s wholly owned subsidiary, Health Management Corporation of America (“HMCA”), has the controlling interest, in Health Diagnostics Management, LLC (“HDM”). HMCA presently has a direct ownership interest of 70.0% in HDM, and the investors in HDM have a 30.0% ownership interest. The management of the diagnostic imaging centers business segment is being conducted by HDM, operating under the name “Health Management Company of America”. For the sake of simplicity, HMCA, and HDM are referred to as “HMCA”, unless otherwise indicated.

The most significant adverse impact on our Company in fiscal 2020 and the first two quarters of fiscal 2021 has been the COVID-19 pandemic. Although it had seemed the worst had passed, events in the last months of 2020 and beginning of 2021 have shown a spike in new cases, including mutations. Although a vaccine has been developed, its distribution is still in the early stages. This is by no means a problem confined to our Company, but regardless of our best efforts, the impact on our results of operation and financial condition is potentially volatile and severe.

Since March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which have adversely affected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally in the beginning COVID-19 caused us to require that much of our workforce work from home and restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the scan volume has risen. During the fourth quarter of fiscal 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and prevent further losses or additional decreases in scan volume. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, particularly in light of recent spikes in new COVID-19 cases, the Company believes with the positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

Page 26

FONAR CORPORATION AND SUBSIDIARIES

Forward Looking Statements

Certain statements made in this Quarterly Report on Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of Management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statement included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.

Results of Operations

We operate in two industry segments: the manufacture and servicing of medical (MRI) equipment, which is conducted by Fonar, and diagnostic facilities management services, which is conducted through HMCA.

Manufacturing and Service of MRI Equipment

Revenues from MRI product sales decreased to $31,000 for the first six months of fiscal 2021 from $195,000 for the first six months of fiscal 2020. Costs related to product sales decreased from $450,000 for the six month period ended December 31, 2019 to $325,000 for the six month period ended December 31, 2020. Economic uncertainty and lower reimbursement rates for MRI scans, have depressed the market for our MRI scanner products, notwithstanding our scanners’ unique technological capabilities (e.g. multi positional scanning). Due to the low sales volumes of our MRI product, period to period comparisons are not necessarily indicative of any trends.

Service revenues decreased by 7.6% from $4.1 million for the six month period ended December 31, 2019 to $3.8 million for the six month period ended December 31, 2020. Continuing lower sales volumes have been a factor ultimately contributing to the decrease in service revenues, as the revenue from new scanners being placed under service agreements, following the expiration of their warranties, is insufficient to replace the revenue lost as a result of older scanners being taken out of service.

Costs relating to providing service were $1.5 million in the first six months of fiscal 2020 and $1.3 million in the first six months of fiscal 2021. Because of our ability to monitor the performance of customers’ scanners from our facilities in Melville, New York on a daily basis and to detect and repair any irregularities before more serious and costly problems develop, we have been able to control our costs of providing service.

There were approximately $205,000 in foreign revenues for the first six months of fiscal 2021 as compared to approximately $307,000 in foreign revenues for the first three months of fiscal 2020, representing an decrease in foreign revenues of 33.2%. We do not regard this as a material trend, but as part of a normal although sometimes volatile variation resulting from low volumes of foreign sales.

We recognize MRI scanner sales revenues on the “percentage of completion” basis, which means the revenues are recognized as the scanner is manufactured. Revenues recognized in a particular quarter do not necessarily reflect new orders or progress payments made by customers in that quarter. We build the scanner as the customer meets certain benchmarks in its site preparation in order to minimize the time lag between incurring costs of manufacturing and our receipt of the cash progress payments from the customer which are due upon delivery. Consequently, there can be a disparity between the revenues recognized in a fiscal period and the number of product sales. Generally, the revenues from a scanner sale are recognized in a fiscal quarter or quarters following the quarter in which the sale was made.

Page 27

FONAR CORPORATION AND SUBSIDIARIES

Revenues for the medical equipment segment decreased to $3.9 million for the first six months of fiscal 2021 from $4.4 million for the first six months of fiscal 2020. Operating losses for our medical equipment segment decreased to an operating loss of $569,000, for the first six months of fiscal 2021 as compared to an operating loss of $1.5 million for the first six months of fiscal 2020.

Diagnostic Facilities Management Services

HMCA revenues decreased in the first six months of fiscal 2021 by 1.3% to $38.3 million from $38.8 million for the first six months of fiscal 2020. The percentage of our revenues derived from our diagnostic facilities management segment relative to the percentage of our revenues derived from our medical equipment segment increased slightly to 90.8% for the first six months of fiscal 2021, from 89.9% for the first six months of fiscal 2020.

HMCA’s strategy is to counter the effects of lower reimbursement rates by increasing the scan volume of the facilities it owns or manages by adding additional scanners at current centers and increasing our marketing efforts. As a result of the COVID-19 virus, however, the Company has seen its scan volume decrease. Nevertheless, the Company is continuing its program of adding additional scanners, even though the COVID-19 virus may delay the completion of the installation of some of the scanners. If scan volumes decrease further, or remain at lower volumes, the Company, notwithstanding its ample cash reserves, may need to reduce the size of its operations as a last resort.

Although the COVID-19 virus had adversely affected our marketing efforts our scan volumes in fiscal 2020, the number of scans performed at our centers and at our client’s centers has still not recovered to pre-COVID-19 levels, decreasing from approximately 89,000 in the first six months of fiscal 2020 to approximately 86,000 in the first six months of fiscal 2021. Our scan volume began to decline in late March 2020 as a result of the impact of the pandemic on referral sources, stay-at-home orders and travel restrictions. The scan volumes going forward in fiscal 2021 may be adversely affected by additional spikes in the COVID-19 virus if sufficiently severe.

We now manage/own a total of 37 MRI scanners. Twenty-three (23) MRI scanners are located in New York and fourteen (14) are located in Florida. HMCA experienced an operating income of $9.7 million for the first six months of fiscal 2021 compared to operating income of $12.0 million for the first six months of fiscal 2020, the decrease being due to greater increase in costs and expenses.

The ability of HMCA to maintain its profitability is principally due to HMCA’s success in marketing the scanning services of the facilities managed or owned by HMCA, notwithstanding the decrease in reimbursement rates paid for MRI scans by insurers, Medicare and other government programs and the lockdowns imposed as a result of the COVID-19 virus. The reductions in reimbursement rates are not unique to HMCA or HMCA’s clients but are being experienced by the industry in general.

HMCA’s cost of revenues for the first six months of fiscal 2021 as compared to the first six months of fiscal 2020 decreased by 6.0% from $21.2 million to $19.9 million primarily as a result of a decrease in scan volume.

Consolidated

For the first six months of fiscal 2021, our consolidated net revenues decreased by 2.4% to $42.1 million from $43.2 million for the first six months of fiscal 2020, and total costs and expenses increased by 1.0% to $33.0 million from $32.7 million for the first six months of fiscal 2021 and for the first six months of fiscal 2020 respectively. As a result, our operating income decreased to $9.1 million in the first six months of fiscal 2021 as compared to $10.5 million in the first six months of fiscal 2020. An increased selling, general and other administrative costs in particular resulted in the growth of cost and expenses.

Selling, general and administrative expenses increased to $10.7 million in the first six months of fiscal 2021 from $8.5 million in the first six months of fiscal 2020. This increase in selling, general and administrative expenses was due mainly to additional reserves taken on Management Fees. Some of these reserves have been taken in the ordinary course of business and some in connection with the impact of the COVID-19 virus. The compensatory element of stock issuances, which is included in selling, general and administrative expenses, increased from $0 for the first six months of fiscal 2020 to $83,000 for the first six months of fiscal 2021.

Page 28

FONAR CORPORATION AND SUBSIDIARIES

Research and development expenses decreased by 21.9% to $824,000 for the first six months of fiscal 2021 from $1.1 million for the first six months of fiscal 2020.

Interest expense in the first six months of fiscal 2021 decreased by 5.0% to $38,000 from $40,000 in the first six months of fiscal 2020.

Inventories increased to $1.8 million at December 31, 2020 as compared to $1.6 million at June 30, 2020.

Net management fee and medical receivables increased by 5.8% to $53.4 million at December 31, 2020 from $50.5 million at June 30, 2020 as a result of slower collections. The slower collections were primarily due to an increase in no-fault and workers’ compensation revenue, which typically takes longer to collect.

The results of operations for the first six months of fiscal 2021 reflect an decrease in revenues from management, patient and other fees, as compared to the first six months of fiscal 2020 ($38.3 million for the first six months of fiscal 2021 as compared to $38.8 million for the first six months of fiscal 2020), and an decrease in MRI equipment segment revenues ($3.9 million as compared to $4.4 million). Revenues were 9.2% from the MRI equipment segment as compared to 90.8% from HMCA, for the first six months of fiscal 2021, as compared to 10.1% from the MRI equipment segment and 89.9% from HMCA for the first six months of fiscal 2020.

On March 27, 2020, the CARES Act was signed into law and is intended to provide over $2 trillion in stimulus benefits for the U.S. economy. The CARES Act provides for certain federal income tax changes, including an increase in the interest expense tax deduction limitation, the deferral of the employer portion of Social Security payroll taxes, refundable payroll tax credits, net operating loss carryback periods, alternative minimum tax credit refunds and bonus depreciation of qualified improvement property. The federal income tax changes brought about by the CARES Act are complex and further guidance is expected. We received a cash benefit from the ability to receive a full reimbursement of $1.2 million of tax credits relating to the alternative minimum tax credits in the current year plus additional cash benefits from the deferral of the employer portion of Social Security payroll taxes.

As a result of the Patient Protection and Affordable Care Act (PPACA) we have experienced a reduction of reimbursement rates and less interest in our MRI equipment. Any changes to the PPACA may result in further changes in the healthcare industry and our business.

We are committed to improving our operating results and dealing with the challenges posed by legislative and regulatory requirements. Nevertheless, factors beyond our control, such as the COVID-19 virus, the timing and rate of market growth, economic conditions, the availability of credit and payor reimbursement rates, or unexpected expenditures and the timing of such expenditures, make it difficult to forecast future operating results.

As mentioned, one of the effects of the PPACA on our business has been the reduction in Medicare reimbursement rates for MRI scans. This also has resulted in a reduction in the reimbursement rates by commercial insurers and government programs which tie their reimbursement rates to the Medicare rates. Nevertheless, the patient volume of the scanning centers we manage or own has enabled us to maintain healthy operating results in spite of these challenges. We believe we are pursuing the correct policies to cope with these problems and the problems caused by the COVID-19 pandemic, and to improve the Company’s operating results.

Our Upright® MRI (also referred to as the Stand-Up® MRI), together with our works-in-progress, are intended to significantly improve our competitive position.

The Upright® MRI scanner, which operates at 6000 gauss (.6 Tesla) field strength, allows patients to be scanned while standing, sitting, reclining and in multiple flexion and extension positions. It is common in visualizing the spine that abnormalities are visualized in some positions and not others. This enables surgical corrections that heretofore would not have been addressable for lack of visualizing the symptom causing the pathology and therefore, in general enables the treating physician to achieve a better treatment outcome for his patient. A floor-recessed elevator brings the patient to the height appropriate for the targeted image region. A custom-built multi-position adjustable bed will allow patients to sit or lie on their backs, sides or stomachs at any angle. This allows the MRI technologist to ask the patient to position himself/herself in the exact position that generates his/her pain so that images of the patient in the position that explicitly generates the patient’s pain can be nailed down. Full-range-of-motion studies of the joints in virtually any direction are possible, a particularly promising feature for sports injuries.

Page 29

FONAR CORPORATION AND SUBSIDIARIES

In addition FONAR has announced the publication of a book “THE CRANIOCERVICAL SYNDROME and MRI” that highlights the unique attributes of FONAR UPRIGHT® MRI Imaging (S. Karger, A.G. based in Basel, Switzerland- www.karger.com/Book/Home/261956) which has been published by S. Karger, an approximately 125 year old company and an academic publisher of scientific and medical journals and books. The seven chapter monograph examines the rapid advances in MRI made possible by the FONAR UPRIGHT® Multi-Position MRI that are transforming the treatment of patients suffering from the craniocervical syndrome (CCS). It is written by leading international experts in the field to practitioners with a better understanding of the subtle anatomy and MRI appearances at the craniocervical junction, along with insight into the clinical significance of cerebrospinal fluid (CSF) flow measurements and its potential role in generating the devastating impairments of the neurodegenerative diseases: Alzheimer’s (5.1 million patients in the United States), childhood and adult Autism (3.0 million), Parkinson’s (1.0 million), Multiple Sclerosis (250,000-350,000) and Amyotrophic Lateral Sclerosis (ALS) (30,000). It calls attention to the revolutionary importance of FONAR’s UPRIGHT® MRI imaging technology and the prospect of significantly relieving the suffering of the above totaled 9.38 million patients afflicted with these disorders.

Fonar also announced a major diagnostic breakthrough in multiple sclerosis achieved with advanced Upright® MRI. Medical researchers at FONAR published a paper reporting a diagnostic breakthrough in multiple sclerosis (MS), based on observations made possible by the Company’s unique Upright® Multi-Position™ MRI scanner. The findings reveal that the cause of multiple sclerosis may be biomechanical and related to earlier trauma to the neck, which can result in obstruction of the flow of cerebrospinal fluid (CSF), which is produced and stored in the central anatomic structures of the brain known as the ventricles. Since the ventricles produce a large net volume of CSF each day (500 cc), the obstruction can result in a build up of pressure within the ventricles, resulting in leakage of the CSF and the antigenic polypeptides it contains into the surrounding brain tissue. This leakage could be responsible for generating the brain lesions of multiple sclerosis.

The paper, titled “The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis," appears in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011).

This capability of the Fonar Upright® technology has demonstrated its key value on patients with the Arnold-Chiari syndrome [Cerebellar Tonsil Extopia (CTE)], which is believed to affect 200,000 to 500,000 Americans. In this syndrome, brain stem compression and subsequent severe neurological symptoms occur in these patients, because the brain stem descends and is compressed at the base of the skull in the foramen magnum, which is the circular bony opening at the base of the skull where the spinal cord exits the skull. Conventional lie-down MRI scanners cannot make an adequate evaluation of this pathology since the patient's pathology is most visible and the symptoms most acute when the patient is scanned in the upright fully weight-bearing position.

A combined study of 1,200 neck pain patients published in “Brain Injury” (July 2010) by eight university medical centers reported that cerebellar tonsil ectopia (CTE) of 1mm or greater was found and visualized 2.5 times (250%) more frequently when patients who had sustained automobile whiplash injuries were scanned upright rather than lying down.

The Upright® MRI has also demonstrated its value for patients suffering from scoliosis. Scoliosis patients have been typically subjected to routine x-ray exams for years and must be imaged upright for an adequate evaluation of their scoliosis. Because the patient must be standing for a complete evaluation of the extent of the patient’s scoliosis, an x-ray machine has been the only modality that could provide that service. The Upright® MRI is the only MRI scanner which allows the patient to stand during the MRI exam. Fonar has developed an RF receiver and scanning protocol that for the first time allows scoliosis patients to obtain diagnostic pictures of their spines without the risks of x-rays. A study by the National Cancer Institute (2000) of 5,466 women with scoliosis reported a 70% increase in breast cancer resulting from 24.7 chest x-rays these patients received on the average in the course of their scoliosis treatment. The Upright® MRI examination of scoliosis enables the needed imaging evaluation of the degree of spine scoliosis without exposing the patient to the risk of breast cancer from x-radiation. Currently scoliosis affects more than 3,000,000 American women.

In addition, the University of California, Los Angeles (UCLA) reported their results of their study of 1,302 patients utilizing the Fonar Upright® MRI at the 22nd Annual Meeting of the North American Spine Society on October 23, 2007. The UCLA study showed the superior ability of the Fonar Upright® MRI to detect spine pathology, including spondylolisthesis, disc herniations and disc degeneration, as compared to visualizations of the spine produced by traditional single position static MRIs.

Page 30

FONAR CORPORATION AND SUBSIDIARIES

The UCLA study by MRI of 1,302 back pain patients when they were in the Fonar Upright® MRI and examined in a full range of flexion and extension positions made possible by Fonar’s new Upright® technology established that significant “misses” of pathology were occurring with static single position MRI imaging. At L4-5, the vertebral level responsible for 49.8% of lumbar disc herniations, 35.1% of the spondylolistheses (vertebral instabilities) visualized by the Upright® MRI, were being missed by static single position MRI (510 patients). Since this vertebral segment is responsible for the majority of all disc herniations, the finding may reveal a significant cause of failed back surgeries. The UCLA study further showed the “miss-rate” of vertebral instabilities by static only MRI was even higher, 38.7%, at the L3-4 vertebral segment. Additionally, the UCLA study showed that MRI examinations of the cervical spine that did not perform extension images of the neck “missed” disc bulges 23.75% of the time (163 patients).

The UCLA study further reported that they were able to quantitatively measure the dimensions of the central spinal canal with the “highest accuracy” using the FONAR Upright® MRI thereby enabling the extent of spinal canal stenosis that existed in patients to be measured. Spinal canal stenosis gives rise to the symptom complex intermittent neurogenic claudication manifest as debilitating pain in the back and lower extremities, weakness and difficulties in ambulation and leg paresthesias. Spinal canal stenosis is a spinal compression syndrome separate and distinct from the more common nerve compression syndrome of the spinal nerves as they exit the vertebral column through the bony neural foramen.

The Fonar Upright® MRI can also be useful for MRI directed emergency neuro-surgical procedures as the surgeon would have unhindered access to the patient’s head when the patient is supine with no restrictions in the vertical direction. This easy-entry, mid-field-strength scanner could prove ideal for trauma centers where a quick MRI-screening within the first critical hour of treatment will greatly improve patients’ chances for survival and optimize the extent of recovery.

MRI has brought a new dimension to MEDICAL TREATMENT, the power to VISUALIZE ANATOMIC DETAIL in the body's VITAL SOFT TISSUES (brain, heart, kidney, liver, spleen, lungs, pancreas, intestines) plus MRI's new power to non-invasively QUANTIFY (e.g. measure T1, T2, diffusion, chemical spectra) the response of these VITAL TISSUES to treatment.

Liquidity and Capital Resources

Cash and cash equivalents, and short term investments increased by 10.3% from $36.8 million at June 30, 2020 to $40.6 million at December 31, 2020.

Cash provided by operating activities for the first six months of fiscal 2021 was $9.6 million. Cash provided by operating activities was attributable principally to net income of $7.2 million, depreciation and amortization of $2.0 million, amortization on right-to-use assets of $1.9 million, provision for bad debts of $2.8 million and deferred income tax of $2.0 million, offset by an increase in accounts, management fee receivables and medical receivables of $5.5 million, a decrease in other current liabilities of $2.7 million and a decrease in operating lease liabilities of $1.7 million.

Cash used by investing activities for the first six months of fiscal 2021 was $2.2 million. Cash used by investing activities was attributable during the first six months of fiscal 2021 consisted of patent costs of $90,000 and the purchase of property and equipment of $2.1 million.

Cash used in financing activities for the first six months of fiscal 2021 was $3.5 million. The principal uses of cash in financing activities during the first six months of fiscal 2021 were the repayment of principal on long-term debt and capital lease obligations of $35,000 and distributions to non-controlling interests of $3.6 million, offset by the proceeds from debt of $63,000.

Total liabilities decreased by 6.9% to $50.3 million at December 31, 2020 from $54.0 million at June 30, 2020. “Other” current liabilities decreased by 31.8% to $5.6 million at December 31, 2020 from $8.2 million at June 30, 2020. Long-term debt and capital lease obligations decreased from $2.1 million at June 30, 2020 to $1.9 million at December 31, 2020. The current portion of our unearned revenue on service contracts decreased from $4.1 million at June 30, 2020 to $4.0 million at December 31, 2020. Customer deposits increased from $855,000 at June 30, 2020 to $1.2 million at December 31, 2020 as a result of an increase in services performed.

Page 31

FONAR CORPORATION AND SUBSIDIARIES

As of December 31, 2020, the total of $5.6 million in “other” current liabilities included accrued salaries and payroll taxes of $2.6 million, and sales taxes of $1.1 million plus accrued interest and penalties of $466,000.

Our working capital increased to $84.7 million at December 31, 2020 from $77.2 million at June 30, 2020. This resulted from an increase in current assets ($95.9 million at June 30, 2020 as compared to $101.6 million at December 31, 2020), and a decrease in current liabilities from $18.7 million at June 30, 2020 to $16.9 million at December 31, 2020. This results from the Company’s care in selecting investments and capital expenditures.

The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At the present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, (principally related to research and development tax credits and allowance for doubtful accounts). A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of any portion or all of the valuation allowance.

The Company’s effective income tax rate is based on expected income, statutory rates and tax planning opportunities available in the various jurisdictions in which it operates. For interim financial reporting, the Company estimates the annual income tax rate based on projected taxable income for the full year and records a quarterly income tax provision or benefit in accordance with the anticipated annual rate. The Company refines the estimates of the year’s taxable income on a periodic basis as new information becomes available, including actual year-to-date financial results. This continual estimation process often results in a change to the expected effective income tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected income tax rate. Significant judgment is required in determining the effective tax rate and in evaluating tax positions.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, (Topic 606). ASU 2014-09 requires an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled in exchange for goods and services as it transfers control to its customers. It also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company earns revenue from the sale of scanners, maintenance contracts, product upgrades, patient services and management fees. Under the new guidance, the reporting for patient services revenue is now reported differently. All other streams of revenue were not impacted by the new guidance. The primary change for healthcare providers under the new guidance relates to revenue generated from patient services, with patient responsibility for payment. Under the new guidance, the Company is required to report an implicit price concession (both initially and for the subsequent changes in estimates) as a reduction of revenues as opposed to bad debt expense as a component of operating expenses. The Company now records any changes in expectation of collection amounts due to patient specific events that suggests that the patient no longer has the ability and intent to pay the amount due through the bad debt expense, as that is more indicative of a change in the customer’s credit worthiness as opposed to change in the transaction price.

The new standard supersedes most current revenue guidance, including industry-specific guidance. The guidance became effective for the Company on July 1, 2018 and as part of adopting the standard, the Company identified revenue streams of like contracts to allow for ease of implementation. The Company used primarily a portfolio approach to apply the new model to classes of customers with similar characteristics. The impact of adopting the new standard on our total revenue; and income from operations was not material. While the adoption of ASU 2014-09 did impact the presentation of net operating revenues in our Consolidated Statements of Operations and impacts certain disclosures, it did not materially impact our financial position, results of operations or cash flows. There was no cumulative effect of a change in accounting principle recorded related to the adoption of ASU 2014-09 on July 1, 2018.

Page 32

FONAR CORPORATION AND SUBSIDIARIES

On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and the creation of refundable employee retention credits. At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1.2 million of tax credits relating to the alternative minimum tax credits in the current year. Before the CARES Act, these credits were to be refunded over a period of 3 years. We will also realize a cash benefit from the deferral of Social Security payroll taxes.

On June 30, 2020, we entered into a $701,000 loan agreement under the Paycheck Protection Program (PPP) under the CARES Act that provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses. The Company applied for this additional loan exclusively for the Florida locations during June 2020 due to the fact that the COIVD-19 virus was increasing in Florida. The loans and accrued interest are forgivable after 24 weeks as long as the proceeds are used for eligible purposes, including payroll, benefits, rent and utilities and maintains certain payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the 24 week period. The Company believes that most it not all of the loan proceeds will be forgiven, however there is no assurance that it will be forgiven until approval is received.

Fonar has not committed to making any significant capital expenditures for the remainder of the 2021 fiscal year with the exception of placing an additional scanner at a facility located in New York.

Critical to our business plan are the improvement and expansion of the MRI facilities managed or owned by HMCA, and increasing the number of scans performed at those facilities. In addition, our business plan calls for a continuing commitment to providing our customers with enhanced equipment service and maintenance capabilities and delivering state-of-the-art, innovative and high quality equipment and upgrades at competitive prices.

Management is seeking to promote wider market recognition of Fonar’s scanner products, and to increase demand for Upright® scanning at the facilities HMCA owns or manages. Given the liquidity and credit constraints in the markets, the uncertainty resulting from the Patient Protection and Affordable Care Act or its repeal or modification, and the impact of the COVID-19 virus on the economy in general, the sale of medical equipment has and may continue to suffer.

The Company believes that its business plan has been responsible for the past eight consecutive fiscal years and first six months of fiscal 2021 profitability and that its capital resources will be adequate to support operations through at least December 31, 2021. The future effects on our business of healthcare legislation, the impact of the COVID-19 virus, the Deficit Reduction Act, the 2.3% excise tax on sales of medical equipment, reimbursement rates, public health conditions and the general economic and business climate are not known at the present time. Nevertheless, there is a possibility of adverse consequences to our business operations from these causes. Although the Company can not predict the full effect of COVID-19 for the first fiscal quarter or any later period, the Company believes that it has adequate revenues, cash reserves and other assets that will enable it to continue to operate until at least December 31, 2021.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company maintains its funds in liquid accounts. None of our investments are in fixed rate instruments.

All of our revenue, expense and capital purchasing activities are transacted in United States dollars.

Page 33

FONAR CORPORATION AND SUBSIDIARIES

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We carried out an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the ‘‘Exchange Act’’). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our chief executive officer and chief financial officer has concluded that the Company’s internal control over financial reporting was effective as of the December 31, 2020, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the same time periods specified in the Securities and Exchange Commission rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our system of internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings: There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

Item 1A – Risk Factors: An investment in the securities of the Company is subject to various risks, the most significant of which are summarized below.

1. Reduced Reimbursement Rates. Most of our revenues are derived from our scanning center business conducted by HMCA. Our scanning center clients and the Florida facilities owned by HMCA are experiencing lower reimbursement rates from Medicare, other government programs and private insurance companies. To date, the impact of these reductions has been countered by increasing scanning volume, increased reimbursement rates with other payors, and reducing our operating expenses, thereby maintaining profitability in this business segment. There is, however, no assurance that we will be able to continue to do so, particularly in light of the COVID-19 pandemic, which has resulted in a decrease in scan volume.

2. Demand for MRI Scanners. The reduced reimbursement rates and COVID-19 pandemic, also affects our sales of MRI scanners negatively. With lower revenue projections, fewer prospective customers will be able to operate, and others are likely to demand lower prices for scanners. Although the reduced reimbursements may not affect foreign demand, a lower number of sales in the aggregate could reduce economies of scale and consequently, profit margins. The demand for MRI scanners could be further reduced by any downturn in the economy resulting from the COVID-19 virus.

3. Manufacturing Competition. Many if not most of our competing scanner manufacturers have significantly greater financial resources, production capacity, and other resources than we do. Such competitors would include General Electric, Siemens, Hitachi and Phillips. Although Fonar is the only company which can manufacture and sell the unique Stand-Up® (Upright®) MRI scanner, potential customers must be convinced that the purchase of a Fonar scanner is their best choice. We believe that with time, that objective will be reached, particularly with customers scanning patients having neck, back, knee and various orthopedic issues who would benefit from being scanned in weight-bearing positions.

Page 34

FONAR CORPORATION AND SUBSIDIARIES

4. Dependence on Referrals. HMCA derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at the facilities. We depend on referrals of patients from unaffiliated physicians and other third parties to the facilities we manage or own for the MRI scanning services performed. If these physicians and other third parties were to reduce the number of patients they refer or discontinue referring patients, scan volumes could decrease, which would have the effect of reducing our net revenue, from both management and scanning fees, and operating margins.

5. Pressure to Control Healthcare Costs. One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost of healthcare services. Healthcare providers participating in managed care plans may be required to refer diagnostic imaging tests to certain providers depending on the plan in which a covered patient is enrolled. In addition, managed care contracting has become very competitive. The expansion of health maintenance organizations, preferred provider organizations and other managed care organizations in New York or Florida could have a negative impact on the utilization and pricing of services performed at the facilities HMCA manages or owns to the extent these organizations exert control over patients’ access to diagnostic imaging services, selections of the provider of such services and reimbursement rates for those services. Pressure to reduce healthcare costs results from government action, such as the reduction of Medicare reimbursements for MRI scans. This provides an additional basis to lower reimbursement levels from private payors, who often base their reimbursement rates on the Medicare rates.

6. Scanning Facility Competition. The market for diagnostic imaging services is highly competitive. The facilities we manage or own compete for patients on the basis of reputation, location and the quality of diagnostic imaging services. Groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment are the principal competitors.

7. Eligibility Changes to Insurance Programs. Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. Healthcare reform legislation may increase the participation of individuals in the Medicaid program in states that elect to participate in the expanded Medicaid coverage, subject to any changes which may result from efforts to repeal and replace the PPACA. A shift in payor mix from managed care and other private payors to government payors or an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Policies now being offered under various insurance plans are expected to reduce demand for MRI scans as they become less affordable. Changes in the eligibility requirements for governmental programs such as the Medicaid program and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors and events could have a material adverse effect on our business, financial condition, and results of operations.

8. Possible changes in Florida Insurance Law. In early 2019, two senate bills and one house bill in Florida were introduced, all of them calling for the repeal of PIP and replacing PI with $25,000 Bodily Injury Coverage and Property Damage Liability Coverage. Another Florida senate bill was introduced that would preserve PIP but dramatically cut reimbursement rates. None of the proposed bills ever made it onto the 2019 legislative agenda, but similar efforts in the future might be successful. Currently, drivers and passengers get car damages and PIP paid for up to $10,000, no matter who is at fault in an accident. Drivers have to pay an additional cost to insurance companies to pay for bodily injuries, which covers them if they are at fault. While PIP is required, coverage for bodily injury is not. Over the past several years there have been various bills introduced by a number of Florida legislators to eliminate PIP and instead mandate coverage including some combination of a minimum of bodily injury and a reduced or no amount of medical payments (Medpay coverage). Eliminating PIP would mean that the $10,000 drivers now get paid toward medical costs through their insurers might not be there for them to pay for injured drivers. Importantly, payments would be reduced by approximately 60% due to claims being paid at commercial rates or through legal settlements instead of at the presently prevailing PIP fee schedule. This would negatively impact our eight diagnostic imaging facilities (both those we own and those we manage) with more unpaid bills, lower reimbursement rates and elongated waiting times. The recent bills, which were introduced in 2020, gained no traction.

Page 35

FONAR CORPORATION AND SUBSIDIARIES

9. Federal and state privacy and information security laws. We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and privacy of Protected Health Information (‘PHI’), including Health Insurance Portability and Accountability Act (‘HIPAA’) and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health (‘HITECH’) Act and collectively referred to as HIPAA. If we fail to comply with applicable privacy and security laws, regulations and standards, properly maintain the integrity of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the use of the internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state agents. Our operations rely on the secure processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks.

10. COVID-19. Although we believe we have taken the proper steps and were making a good recovery from the impact of COVID-19 virus, the recent increase in new cases and mutations of COVID-19 and in the recent months, may have an economic and medical impact that would materially and adversely affect our business. The mitigating effect of new vaccines remains to be seen.

11. Other changes in Domestic and Worldwide Economic Conditions. We are subject to risk arising from adverse changes in general domestic and global economic and other conditions, including a prolonged period of the COVID-19 pandemic, recessions or economic slowdowns and disruptions of credit markets. Turbulence and uncertainty in the United States and international markets and economies may adversely affect our workforce, liquidity, financial condition, revenues, profitability and business operations generally.

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds: None

Item 3 - Defaults Upon Senior Securities: None

Item 4 - Mine Safety Disclosure: Not Applicable

Item 5 - Other Information: None

Item 6 - Exhibits and Reports on Form 8-K:

Exhibit 31.1 Certification. See Exhibits

Exhibit 32.1 Certification. See Exhibits

Report on Form 8-K filed on November 13, 2020, Item 2.02: Results of Operations and Financial Condition for the fiscal quarter ended September 30, 2020.

Page 36

FONAR CORPORATION AND SUBSIDIARIES

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FONAR CORPORATION

(Registrant)

________________

By: /s/ Timothy Damadian

Timothy Damadian

President and

Principal Executive Officer

________________

/s/ Raymond V. Damadian

Raymond V. Damadian

Chairman of the Board,

Treasurer and

Acting Principal Financial Officer

Dated: February 16, 2021

Page 37

GRAPHIC 2 fonar-logo.jpg GRAPHIC begin 644 fonar-logo.jpg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end

EX-31.1 3 fonar_exhibit-31.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION

Timothy Damadian and Raymond V. Damadian each certify that:

I have reviewed this report on Form 10-Q of Fonar Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f) for the registrant and have:

designed such disclosure controls and procedures or caused such disclosure controls over procedures to be designed under my supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 16, 2021

____________________________

/s/ Timothy Damadian

Timothy Damadian

President and

Principal Executive Officer

____________________________

/s/ Raymond V. Damadian

Raymond V. Damadian

Chairman of the Board, Treasurer and

Acting Principal Financial Officer

EX-32.1 4 fonar_exhibit-32.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of FONAR Corporation and Subsidiaries (the “Company”) on Form 10Q for the fiscal quarter ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy Damadian, President and Chief Executive Officer, and I, Raymond V. Damadian, Chairman of the Board, Treasurer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/Timothy Damadian

____________________________

Timothy Damadian

President and Chief Executive Officer

/s/ Raymond V. Damadian

____________________________

Raymond V. Damadian

Chairman of the Board, Treasurer and

Chief Financial Officer

February 16, 2021

A signed original of this written statement required by Section 906 has been provided to Fonar Corporation and will be retained by Fonar Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.PRE 5 fonr-20201231_pre.xml XBRL PRESENTATION FILE EX-101.LAB 6 fonr-20201231_lab.xml XBRL LABEL FILE Equity Components [Axis] Accumulated Deficit Class of Stock [Axis] Common Stock Class C Common Stock Statement, Operating Activities Segment [Axis] Medical Equipment Management Of Diagnostic Imaging Centers Class B Common Stock AccountsNotesLoansAndFinancingReceivableByReceivableType [Axis] Gross Receivable Allowance for Doubtful Accounts Finite-Lived Intangible Assets by Major Class [Axis] Capitalized software development costs Patents and copyrights Non-compete Customer relationships Health Care Organization, Revenue Sources [Axis] Workers Compensation/Personal Injury Medicare/Medicaid Commercial Insurance / Managed Care Other Class A Non-Voting Preferred Stock Preferred Stock Paid in capital in excess of par value Treasury Stock Noncontrolling Interest Ownership [Axis] Health Diagnostics Management LLC (HDM) Class A Common Stock Non Controlling Interest Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Document Fiscal Year Focus Current Fiscal Year End Date Document Fiscal Period Focus Amendment Flag Entity File Number Entity Incorporation State Country Code Is Entity Interactive Data Current Is Entity's Reporting Status Current? Is Entity a Small Business Entity Filer Category Is Entity an Emerging Growth Company Entity Common Stock, Shares Outstanding Trading Symbol Security Exchange Name Security 12B Title Entity Shell Company ASSETS Current Assets: Cash and cash equivalents Short term investments Accounts receivable - net Account receivable - related parties Medical receivables -net Management and other fees receivable -net Management and other fees receivable - related medical practices -net Inventories Costs and estimated earnings in excess of billings on uncompleted contracts Income taxes receivable Prepaid expenses and other current assets Total Current Assets Accounts receivable Deferred income tax asset Property and equipment - net Right-of-use Asset - operating lease Right-of-use-asset - financing lease Goodwill Other intangible assets - net Other assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Current portion of long-term debt and capital leases Accounts payable Other current liabilities Unearned revenue on service contracts Unearned revenue on service contracts - related parties Operating lease liability - current portion Financing lease liability - current portion Customer deposits Total Current Liabilities Long-Term Liabilities: Unearned revenue on service contracts Deferred Income Tax Liability Due to related party medical practices Operating lease liability - net of current portion Financing lease liability - net of current portion Long-term debt and capital leases, less current portion Other liabilities Total Long-Term Liabilities Total Liabilities STOCKHOLDERS' EQUITY: Preferred stock value Common stock value Paid-in capital in excess of par value Accumulated deficit Treasury stock, at cost Total Fonar Corporation Stockholder Equity Noncontrolling interests Total Stockholders' Equity Total Liabilities and Stockholders' Equity Preferred Stock, Par Value Preferred Stock, Authorized Preferred Stock, Issued Preferred Stock, Outstanding Common Stock, Par Value Common Stock, Authorized Common Stock, Issued Common Stock, Outstanding REVENUES Patient fee revenue, net of contractual allowances and discounts Product sales - net Service and repair fees - net Service and repair fees - related parties - net Management and other fees - net Management and other fees - related medical practices - net Total Revenues - net COSTS AND EXPENSES Costs related to patient fee revenue Costs related to product sales Costs related to service and repair fees Costs related to service and repair fees - related parties Costs related to management and other fees Costs related to management and other fees - related medical practices Research and development Selling, general and administrative Total Costs and Expenses INCOME Income From Operations Other Expenses Interest Expense Investment Income Income Before Provision for Income Taxes and Noncontrolling Interests Provision for Income Taxes Net Income Net Income - Noncontrolling Interests Net Income - Attributable to FONAR Basic Net Income Per Share Diluted Net Income Per Share Basic and Diluted Income Per Share Weighted Average Basic Shares Outstanding Weighted Average Diluted Shares Outstanding Balance - Beginning, Value Issuance of common stock (value) Net Income Distributions - noncontrolling Income - Noncontrolling interests Balance - Ending, Value Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Amortization on right-of-use assets Provision (Recovery) for bad debts Deferred income tax - net Compensatory element of stock issuances Stock issued for costs and expense Abandoned patents (Increase) decrease in operating assets, net: Accounts, medical and management fee receivable(s) Notes receivable Costs and estimated earnings in excess of billings on uncompleted contracts Inventories Income tax receivable Prepaid expenses and other current assets Other assets Increase (decrease) in operating liabilities, net: Accounts payable Other current liabilities Operating lease liabilities Financing lease liabilities Customer deposits Billings in excess of costs and estimated earnings on uncompleted contracts Other liabilities Net cash provided by operating activities Cash Flows from Investing Activities: Purchases of property and equipment Purchase of short term investment Cost of patents Net cash used in investing activities Cash Flows from Financing Activities: Repayment of borrowings and capital lease obligations Proceeds from debt Distributions to noncontrolling interests Net cash used in financing activities Net Increase in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning of Period Cash and Cash Equivalents - End of Period EX-101.DEF 7 fonr-20201231_def.xml XBRL DEFINITION FILE EX-101.CAL 8 fonr-20201231_cal.xml XBRL CALCULATION FILE EX-101.SCH 9 fonr-20201231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTE 5 - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTE 9 - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTE 13 - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTE 14 - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTE 5 - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NOTE 5 - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - NOTE 9 - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - NOTE 13 - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.INS 10 fonr-20201231.xml XBRL INSTANCE FILE 0000355019 2020-06-30 0000355019 2020-12-31 0000355019 2019-07-01 2019-12-31 0000355019 2020-07-01 2020-12-31 0000355019 us-gaap:RetainedEarningsMember 2019-07-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2019-07-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-07-01 2020-12-31 0000355019 us-gaap:CommonClassCMember 2020-07-01 2020-12-31 0000355019 us-gaap:CommonClassCMember 2019-07-01 2019-12-31 0000355019 us-gaap:RetainedEarningsMember 2020-07-01 2020-12-31 0000355019 FONR:MedicalEquipmentMember 2020-07-01 2020-12-31 0000355019 FONR:MedicalEquipmentMember 2019-07-01 2019-12-31 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2020-07-01 2020-12-31 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2019-07-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2021-02-05 0000355019 us-gaap:CommonClassCMember 2021-02-05 0000355019 us-gaap:CommonClassBMember 2021-02-05 0000355019 us-gaap:AccountsReceivableMember 2020-06-30 0000355019 us-gaap:AccountsReceivableMember 2020-12-31 0000355019 us-gaap:DoubtfulMember 2020-06-30 0000355019 us-gaap:DoubtfulMember 2020-12-31 0000355019 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-06-30 0000355019 FONR:PatentsAndCopyrightsMember 2020-06-30 0000355019 us-gaap:NoncompeteAgreementsMember 2020-06-30 0000355019 us-gaap:CustomerRelationshipsMember 2020-06-30 0000355019 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000355019 FONR:PatentsAndCopyrightsMember 2020-12-31 0000355019 us-gaap:NoncompeteAgreementsMember 2020-12-31 0000355019 us-gaap:CustomerRelationshipsMember 2020-12-31 0000355019 FONR:PatentsAndCopyrightsMember 2020-07-01 2020-12-31 0000355019 FONR:PatentsAndCopyrightsMember 2019-07-01 2019-12-31 0000355019 us-gaap:NoncompeteAgreementsMember 2020-07-01 2020-12-31 0000355019 us-gaap:NoncompeteAgreementsMember 2019-07-01 2019-12-31 0000355019 us-gaap:CustomerRelationshipsMember 2020-07-01 2020-12-31 0000355019 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-12-31 0000355019 us-gaap:CommonStockMember 2020-06-30 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2019-07-01 2019-12-31 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2020-07-01 2020-12-31 0000355019 FONR:MedicareMedicaidMember 2019-07-01 2019-12-31 0000355019 FONR:MedicareMedicaidMember 2020-07-01 2020-12-31 0000355019 FONR:CommercialInsuranceManagedCareMember 2019-07-01 2019-12-31 0000355019 FONR:CommercialInsuranceManagedCareMember 2020-07-01 2020-12-31 0000355019 FONR:OtherRevenueSourceMember 2020-07-01 2020-12-31 0000355019 FONR:OtherRevenueSourceMember 2019-07-01 2019-12-31 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-12-31 0000355019 us-gaap:PreferredStockMember 2020-12-31 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-06-30 0000355019 us-gaap:PreferredStockMember 2020-06-30 0000355019 us-gaap:CommonClassBMember 2020-12-31 0000355019 us-gaap:CommonClassCMember 2020-12-31 0000355019 us-gaap:CommonClassBMember 2020-06-30 0000355019 us-gaap:CommonClassCMember 2020-06-30 0000355019 FONR:ClassANonVotingPreferredStockMember 2019-07-01 2019-12-31 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-07-01 2020-12-31 0000355019 us-gaap:CommonStockMember 2020-07-01 2020-12-31 0000355019 us-gaap:CommonStockMember 2019-07-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-06-30 0000355019 us-gaap:CommonStockMember 2020-12-31 0000355019 us-gaap:CommonStockMember 2019-06-30 0000355019 us-gaap:CommonStockMember 2019-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000355019 us-gaap:RetainedEarningsMember 2020-06-30 0000355019 us-gaap:RetainedEarningsMember 2020-12-31 0000355019 us-gaap:RetainedEarningsMember 2019-06-30 0000355019 us-gaap:RetainedEarningsMember 2019-12-31 0000355019 us-gaap:TreasuryStockMember 2020-07-01 2020-12-31 0000355019 us-gaap:TreasuryStockMember 2019-07-01 2019-12-31 0000355019 us-gaap:TreasuryStockMember 2020-06-30 0000355019 us-gaap:TreasuryStockMember 2020-12-31 0000355019 us-gaap:TreasuryStockMember 2019-06-30 0000355019 us-gaap:TreasuryStockMember 2019-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2020-06-30 0000355019 us-gaap:NoncontrollingInterestMember 2020-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2019-06-30 0000355019 us-gaap:NoncontrollingInterestMember 2019-12-31 0000355019 2019-06-30 0000355019 2019-12-31 0000355019 FONR:HDMMember 2015-07-01 0000355019 us-gaap:CommonClassAMember 2021-02-05 0000355019 2020-10-01 2020-12-31 0000355019 2019-10-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000355019 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000355019 FONR:ClassANonVotingPreferredStockMember 2020-10-01 2020-12-31 0000355019 FONR:ClassANonVotingPreferredStockMember 2019-10-01 2019-12-31 0000355019 us-gaap:CommonClassCMember 2020-10-01 2020-12-31 0000355019 us-gaap:CommonClassCMember 2019-10-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000355019 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000355019 us-gaap:CommonStockMember 2020-09-30 0000355019 us-gaap:CommonStockMember 2019-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000355019 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000355019 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000355019 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000355019 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000355019 us-gaap:RetainedEarningsMember 2020-09-30 0000355019 us-gaap:RetainedEarningsMember 2019-09-30 0000355019 us-gaap:TreasuryStockMember 2020-10-01 2020-12-31 0000355019 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000355019 us-gaap:TreasuryStockMember 2020-09-30 0000355019 us-gaap:TreasuryStockMember 2019-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0000355019 us-gaap:NoncontrollingInterestMember 2020-09-30 0000355019 us-gaap:NoncontrollingInterestMember 2019-09-30 0000355019 2020-09-30 0000355019 2019-09-30 0000355019 FONR:CommercialInsuranceManagedCareMember 2020-10-01 2020-12-31 0000355019 FONR:CommercialInsuranceManagedCareMember 2019-10-01 2019-12-31 0000355019 FONR:MedicareMedicaidMember 2020-10-01 2020-12-31 0000355019 FONR:MedicareMedicaidMember 2019-10-01 2019-12-31 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2020-10-01 2020-12-31 0000355019 FONR:WorkersCompensationPersonalInjuryMember 2019-10-01 2019-12-31 0000355019 FONR:OtherRevenueSourceMember 2020-10-01 2020-12-31 0000355019 FONR:OtherRevenueSourceMember 2019-10-01 2019-12-31 0000355019 FONR:PatentsAndCopyrightsMember 2020-10-01 2020-12-31 0000355019 FONR:PatentsAndCopyrightsMember 2019-10-01 2019-12-31 0000355019 us-gaap:NoncompeteAgreementsMember 2020-10-01 2020-12-31 0000355019 us-gaap:NoncompeteAgreementsMember 2019-10-01 2019-12-31 0000355019 us-gaap:CustomerRelationshipsMember 2019-10-01 2019-12-31 0000355019 us-gaap:CustomerRelationshipsMember 2020-10-01 2020-12-31 0000355019 FONR:MedicalEquipmentMember 2020-10-01 2020-12-31 0000355019 FONR:MedicalEquipmentMember 2019-10-01 2019-12-31 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2020-10-01 2020-12-31 0000355019 FONR:ManagementOfDiagnosticImagingCentersMember 2019-10-01 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

6402000

5619000

6402000

6010000

5281000

86000

100000

5619000

292000

252000

3111000

3104000

2923000

2914000

140000

142000

48000

3111000

3104000

15878000

16062000

6554210 382513 146 313438

14000

35000

228000

145000

19987000

20076000

7005000

5082000

4100000

3800000

7005000

5171000

4100000

3800000

89000

94000

293000

95000

44000

47000

147000

47000

110000

466000

1100000

309000 309000 757000 757000

234000

448000

1962000

2039000

1962000

1544000

1614000

105000

230000

16848000

0.0001

0.001

0.0001

0.001

453000

567000

453000

567000

313000

0.0001

8500000

227000

567000

227000

567000

6566000

6459000

146

383000

146

383000

3735000

3570000

3735000

2130000

1980000

2130000

1980000

-2313000

-1560000

-2313000

-817000

-1105000

-817000

-1105000

FONAR CORP 0000355019 10-Q 2020-12-31 2021 --06-30 Q2 false 0-10248 DE Yes Yes true Non-accelerated Filer false FONR NASDAQ Common Stock 153000 153000 false

126242000

131876000

1000

183076000

185101000

181086000

183076000

-56215000

-50596000

-64455000

-58053000

-675000

55000

-1955000

2156000

734000

118113000

125083000

1000

183076000

-53707000

-61157000

-675000

-642000

1609000

128053000

122854000

47208000

0.63 0.66 0.66 0.60 0.111 0.128 0.127 0.111

700000

789000

877000

511000

87000

123000

120000

180000

113000

276000

1353000

1123000

443000

9000

4492000

2573000

In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020. The Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period. -604000 -604000 202000

33300000

1990000

2025000

1990000

2025000

180259000

182148000

653000

632000

4109000

4014000

3985000

1326000

1226000

31392000

29570000

21364000

21683000

18810000

16848000

2730000 2594000

95890000

101596000

1758000

1302000

671000

153000

1649000

1844000

6000 72000

32000

36802000

40579000

54017000

50272000

35354000

33349000

150000

148000

865000

780000

1251000

1151000

30105000

28415000

93000

234000

2656000

2528000

18663000

16923000

855000

1232000

75000

200000

3370000

3403000

55000

4105000

4029000

8185000

5584000

1965000

2198000

108000

222000

180259000

182148000

55000

-1955000

126187000

133831000

675000

-56215000

-50596000

183076000

185101000

1000

43197000

42144000

21164000

21451000

4780000 5386000 2693000 2390000 22024000 22554000 11340000 10996000 55000 55000 28000 28000 4102000 3788000 1862000 2038000 195000 31000 3000 3000

32690000

33012000

16182000

16430000

8458000

10704000

4541000

4163000

1055000

824000

424000

583000

3157000 2950000 1522000 1621000 12208000 11788000 6237000 6203000 20000 18000 9000 10000 1522000 1234000 608000 772000 450000 325000 192000 120000

5820000

5169000

2649000

2958000

8715000

7179000

3928000

4209000

2039000

1962000

1113000

932000

10754000

9141000

5041000

5141000

287000

187000

75000

139000

40000

38000

16000

19000

10507000

9132000

4982000

5021000

0.23

0.26

0.12

0.13

140000

10187000

9552000

123000

-3000

-12000

28000

378000

24000

-1447000

-1657000

430000

-2748000

-576000

233000

45000

1000

-330000

-452000

-671000

-47000

195000

-372000

-11000

-25000

4300000

5549000

1000

1990000

1941000

83000

1816000

1962000

-978000 2825000

1656000

1922000

2003000

2009000

-4917000

-2233000

62000

90000

199000

4656000

2143000

36802000

40579000

13882000

15393000

1511000

3777000

-3759000

-3542000

63000

24000

35000

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION   Description of Business   Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name “Health Management Company of America”.   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on October 1, 2020 for the fiscal year ended June 30, 2020.   During March 2020 the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations. Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel to travel for marketing purposes or to service our customers. The Company experienced a sudden drop in scan volume for a short term period and while the Company is not back to pre-COVID-19 levels, the volume has risen. At the end of fiscal year ending June 30, 2020, the Company was able to enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in scan volume. The Company immediately enacted wide scale furloughs, deferment of up to 50% of management salaries, halted variable compensation plans and rent deferrals we negotiated with the majority of all landlords. The Company also received some government stimulus funds from the Paycheck Protection Program (“PPP”) and Medicare advances/stimulus payments. Although we are unable to predict if there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive cash flows, low debt and cash on hand, it will be able to continue operations going forward.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Principles of Consolidation   The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.   Revenues   On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.   Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.   Earnings Per Share   Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three and six months ended December 31, 2020 and 2019.   Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,111</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,923</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,104</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,914</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,465</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,447</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,593</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,575</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,619</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,281</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">86</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,402</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,010</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">100</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.87</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.99</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.93</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,456</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,440</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,584</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,568</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.80</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.92</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Recent Accounting Pronouncements   In December 2019, the FASB issued ASU 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are current evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of the adoption.   In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.   FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.    Reclassifications    Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE   Receivables, net is comprised of the following at December 31, 2020, and June 30, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Gross Receivable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">   Allowance for doubtful accounts</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Net</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable</td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,686</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">515</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,171</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable - related party</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">72</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Medical receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,373</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,373</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,298</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,490</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">29,808</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable from related medical practices ("PC’s")</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,982</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,720</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">7,262</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Gross Receivable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">   Allowance for doubtful accounts</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Net</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable</td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,828</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">515</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,313</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable - related party</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Medical receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,172</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,172</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">38,501</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">11,063</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">27,438</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable from related medical practices ("PC’s")</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,218</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,322</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,896</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The Company's customers are concentrated in the healthcare industry.   Accounts Receivable   Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.   Long Term Accounts Receivable   The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; text-align: right">2022</td> <td style="width: 1%"> </td> <td style="width: 7%"> </td> <td style="width: 1%">$</td> <td style="width: 45%; text-align: right">853</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">827</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">752</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">2025</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">96</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,528</td></tr> </table>   Medical Receivables   Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.   Management and Other Fees Receivable   The Company's receivables from the related and non-related professional corporations (PC's) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC's of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.   Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66% and 60% of the PCs’ net revenues for the three months ended December 31, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. Approximately 66% and 63% of the PCs’ net revenue for the six months ended December 31, 2020 and 2019, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management's expectations.    Net revenues from management and other fees charged to the related PCs accounted for approximately 12.7% and 11.1% of the consolidated net revenues for the three months ended December 31, 2020 and 2019, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately 12.8% and 11.1% of the consolidated net revenues for the six months ended December 31, 2020 and 2019, respectively.   Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.   The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2020 and 2019 are summarized in the following table.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid"> For the Three Months Ended December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 12.6pt; text-indent: -12.6pt">Commercial Insurance/ Managed Care</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">966</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Medicare/Medicaid</td> <td> </td> <td> </td> <td style="text-align: right">206</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">276</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Workers' Compensation/Personal Injury</td> <td> </td> <td> </td> <td style="text-align: right">3,543</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,112</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">523</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">273</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt">Patient Fee Revenue, net of contractual allowances and discounts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,238</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,996</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid"> For the Six Months Ended December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 12.6pt; text-indent: -12.6pt">Commercial Insurance/ Managed Care</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,912</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,689</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Medicare/Medicaid</td> <td> </td> <td> </td> <td style="text-align: right">404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">542</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Workers' Compensation/Personal Injury</td> <td> </td> <td> </td> <td style="text-align: right">6,930</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,406</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,084</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">404</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt">Patient Fee Revenue, net of contractual allowances and discounts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,330</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,041</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 4 – OPERATING & FINANCING LEASES   During February 2016, FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar to existing guidance foOTr operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the time of adoption of this guidance we had no significant financing leases.   The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Also included in other current assets is a $202 receivable from a landlord for tenant improvements. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.   A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1pt solid"> Year Ending December 31,</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Operating Lease Payments</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Financing Lease Payments</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%"> </td> <td style="width: 26%; text-align: right">2021</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 26%; text-align: right">4,960</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 26%; text-align: right">244</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,877</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,599</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,480</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">2025</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,301</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Thereafter</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17,505</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">287</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Present value discount</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(8,904</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(156</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">Total lease liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,818</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,351</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 5 - INVENTORIES   Inventories included in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt">Purchased parts, components and supplies</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,614</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,544</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Work-in-process</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">230</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">105</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,844</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,649</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS   Information relating to uncompleted contracts is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30,  2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 9pt; text-indent: -9pt">Costs incurred on uncompleted contracts</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">448</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">448</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Estimated earnings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">309</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">309</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Subtotal</td> <td> </td> <td> </td> <td style="text-align: right">757</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">757</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Less: Billings to date</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Total Costs and estimated earnings in excess of billings on uncompleted contracts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 7 – OTHER INTANGIBLE ASSETS   Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt">Capitalized software development costs</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,005</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,005</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Patents and copyrights</td> <td> </td> <td> </td> <td style="text-align: right">5,171</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,082</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Non-compete</td> <td> </td> <td> </td> <td style="text-align: right">4,100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,100</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Customer relationships</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,800</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,800</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Other intangible assets</td> <td> </td> <td> </td> <td style="text-align: right">20,076</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,987</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,062</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,878</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Other Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,014</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,109</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>      Amortization of patents and copyrights for the three months ended December 31, 2020 and 2019 amounted to $44 and $47, respectively.   Amortization of non-compete for the three months ended December 31, 2020 and 2019 amounted to $0 and $147, respectively.   Amortization of customer relationships for the three months ended December 31, 2020 and 2019 amounted to $47 and $47, respectively.   Amortization of patents and copyrights for the six months ended December 31, 2020 and 2019 amounted to $89 and $94, respectively.   Amortization of non-compete for the six months ended December 31, 2020 and 2019 amounted to $0 and $293, respectively.   Amortization of customer relationships for the six months ended December 31, 2020 and 2019 amounted to $95 and $95, respectively.

NOTE 8 – OTHER CURRENT LIABILITIES   Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 9pt; text-indent: -9pt">Accrued salaries, commissions and payroll taxes</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,573</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">4,492</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Litigation accruals</td> <td> </td> <td> </td> <td style="text-align: right">9</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">443</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Sales tax payable</td> <td> </td> <td> </td> <td style="text-align: right">1,123</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,353</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Legal and other professional fees</td> <td> </td> <td> </td> <td style="text-align: right">276</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">113</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Accounting fees</td> <td> </td> <td> </td> <td style="text-align: right">180</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Self-funded health insurance reserve</td> <td> </td> <td> </td> <td style="text-align: right">123</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">87</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Accrued interest and penalty</td> <td> </td> <td> </td> <td style="text-align: right">511</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">877</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">789</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">700</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Other Current Liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,584</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,185</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 9 – STOCKHOLDERS EQUITY   Common Stock   During the six months ended December 31, 2020, the Company issued 102 shares of common stock for costs and expenses of $1,941 and 4 shares of common stock to employees and consultants as compensation valued at $83.   During the six months ended December 31, 2019, the Company issued 90 shares of common stock for costs and expenses of $1,990.

NOTE 10 - SEGMENT AND RELATED INFORMATION   The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.   The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.   The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2020. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.   Summarized financial information concerning the Company's reportable segments is shown in the following table:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Medical Equipment</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Management of Diagnostic Imaging Centers</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the three months ended Dec. 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 46%; padding-left: 5.4pt">Net revenues from external customers</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,893</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">19,271</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">21,164</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(8</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">4,990</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4,982</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">65</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">977</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,042</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">70</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,728</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,798</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the three months ended Dec. 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Net revenues from external customers</td> <td> </td> <td>$</td> <td style="text-align: right">2,069</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">19,382</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">21,451</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(790</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">5,811</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5,021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">94</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">914</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,008</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">153</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,269</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Medical Equipment</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Management of Diagnostic Imaging Centers</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the six months ended Dec. 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 46%; padding-left: 5.4pt">Net revenues from external customers</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">3,874</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">38,270</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">42,144</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(569</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">9,701</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">9,132</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">132</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,878</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,010</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,143</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,233</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the six months ended Dec. 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Net revenues from external customers</td> <td> </td> <td>$</td> <td style="text-align: right">4,352</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">38,845</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">43,197</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(1,526</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">12,033</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10,507</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">185</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,818</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">1,754</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,964</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4,718</td> <td> </td></tr> </table>

NOTE 11 – SUPPLEMENTAL CASH FLOW INFORMATION   During the six months ended December 31, 2020 and December 31, 2019, the Company paid $35 and $14 for interest, respectively.   During the six months ended December 31, 2020 and December 31, 2019, the Company paid $145 and $228 for income taxes, respectively.

NOTE 12 – COMMITMENTS AND CONTINGENCIES   Litigation   The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.   There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.   Other Matters   In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.   The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of December 31, 2020, the Company has recorded tax obligations of approximately $1.1 million plus interest and penalties of approximately $466. The Company is in the process of determining the regulatory requirements in order to become compliant.   The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $110 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2020 and June 30, 2020, the Company had approximately $123 and $87, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets.   The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.

NOTE 13 - INCOME TAXES   In accordance with ASC 740-270, Income Taxes – Interim Reporting, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the six months ended December 31, 2020 and 2019, the Company recorded income tax expense of $1,962 in 2020 as compared to $2,039 in 2019. The 2020 provision is comprised of a current income tax component of $0 and a deferred income tax component of $1,962. Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.   ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it has not recorded a liability for unrecognized tax benefits.   In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses.   The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2016.    The Company recorded a deferred tax asset of $16,848 and a deferred tax liability of $234 as of December 31, 2020, primarily relating to net operating loss carryforwards of approximately $47,208 available to offset future taxable income through 2031. The net operating losses begin to expire in 2023 for federal tax and state income tax purposes.   On March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability of AMT tax credits.   At the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.   As we continue to monitor tax implications of the CARES Act and other state and federal stimulus tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities.   Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of December 31, 2020, no such changes in ownership have occurred.   The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to research and development tax credits.   A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.

NOTE 14 – SUBSEQUENT EVENTS   The Company has evaluated events that occurred subsequent to December 31, 2020 and through the date the condensed consolidated financial statements were issued.

Principles of Consolidation   The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenues   On July 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.   Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

Earnings Per Share   Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three and six months ended December 31, 2020 and 2019.   Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2020 and 2019, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,111</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,923</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,104</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,914</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,465</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,447</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,593</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,575</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,619</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,281</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">86</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,402</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,010</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">100</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.87</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.99</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.93</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,456</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,440</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,584</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,568</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.80</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.92</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Recent Accounting Pronouncements   In December 2019, the FASB issued ASU 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other areas of the standard. ASU 2019-12 will be effective beginning in the first quarter of 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. We are current evaluating the impact this ASU will have on our financial statements and related disclosures as well as the timing of the adoption.   In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the Standard on July 1, 2020 and the impact of adopting this guidance will have no material impact on our Consolidated Financial Statements.   FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2020 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2020 or 2019, and it does not believe that any of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.

Reclassifications    Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net income for any periods presented.

Earnings Per Share   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Three months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,111</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,923</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">3,104</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">2,914</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">48</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,465</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,447</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.48</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,465</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,447</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,593</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,575</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.44</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">Six months ended December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Class C Common Stock</td></tr> <tr style="vertical-align: bottom"> <td>Basic</td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt">Numerator:  Net income available to common stockholders</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,619</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">5,281</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">86</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,402</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">6,010</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 6%; text-align: right">100</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,456</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,440</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Basic income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.87</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.99</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.93</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Diluted</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator: Weighted average shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,456</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,440</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 8.85pt; text-indent: -8.85pt">Convertible Class C Stock</td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">128</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Total Denominator for diluted earnings per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,584</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,568</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">383</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 8.85pt; text-indent: -8.85pt">Diluted income per common share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.80</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.23</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.92</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Receivables, net is comprised of the following at December 31, 2020, and June 30, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Gross Receivable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">   Allowance for doubtful accounts</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Net</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable</td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,686</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">515</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,171</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable - related party</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">72</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Medical receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,373</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,373</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,298</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,490</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">29,808</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable from related medical practices ("PC’s")</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,982</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,720</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">7,262</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Gross Receivable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">   Allowance for doubtful accounts</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Net</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable</td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,828</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">515</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">4,313</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Accounts receivable - related party</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Medical receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,172</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">16,172</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">38,501</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">11,063</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">27,438</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 17.1pt; text-indent: -17.1pt">Management and other fees receivable from related medical practices ("PC’s")</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,218</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,322</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,896</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Future revenue to be recognized over the following four years as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; text-align: right">2022</td> <td style="width: 1%"> </td> <td style="width: 7%"> </td> <td style="width: 1%">$</td> <td style="width: 45%; text-align: right">853</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">827</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">752</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">2025</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">96</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,528</td></tr> </table>

The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2020 and 2019 are summarized in the following table.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid"> For the Three Months Ended December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 12.6pt; text-indent: -12.6pt">Commercial Insurance/ Managed Care</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">966</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Medicare/Medicaid</td> <td> </td> <td> </td> <td style="text-align: right">206</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">276</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Workers' Compensation/Personal Injury</td> <td> </td> <td> </td> <td style="text-align: right">3,543</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,112</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">523</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">273</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt">Patient Fee Revenue, net of contractual allowances and discounts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,238</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,996</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid"> For the Six Months Ended December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 12.6pt; text-indent: -12.6pt">Commercial Insurance/ Managed Care</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,912</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,689</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Medicare/Medicaid</td> <td> </td> <td> </td> <td style="text-align: right">404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">542</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 12.6pt; text-indent: -12.6pt">Workers' Compensation/Personal Injury</td> <td> </td> <td> </td> <td style="text-align: right">6,930</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,406</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 12.6pt; text-indent: -12.6pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,084</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">404</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 12.6pt; text-indent: -12.6pt">Patient Fee Revenue, net of contractual allowances and discounts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,330</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,041</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1pt solid"> Year Ending December 31,</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Operating Lease Payments</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Financing Lease Payments</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%"> </td> <td style="width: 26%; text-align: right">2021</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 26%; text-align: right">4,960</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 26%; text-align: right">244</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,877</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,599</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,480</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">2025</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,301</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">244</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Thereafter</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17,505</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">287</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Present value discount</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(8,904</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(156</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">Total lease liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,818</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,351</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt">Purchased parts, components and supplies</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,614</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,544</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Work-in-process</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">230</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">105</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,844</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,649</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Information relating to uncompleted contracts is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30,  2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 9pt; text-indent: -9pt">Costs incurred on uncompleted contracts</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">448</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">448</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Estimated earnings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">309</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">309</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Subtotal</td> <td> </td> <td> </td> <td style="text-align: right">757</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">757</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Less: Billings to date</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Total Costs and estimated earnings in excess of billings on uncompleted contracts</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 5.4pt">Capitalized software development costs</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,005</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,005</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Patents and copyrights</td> <td> </td> <td> </td> <td style="text-align: right">5,171</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,082</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Non-compete</td> <td> </td> <td> </td> <td style="text-align: right">4,100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,100</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Customer relationships</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,800</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,800</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Other intangible assets</td> <td> </td> <td> </td> <td style="text-align: right">20,076</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,987</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,062</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,878</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Other Intangible Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,014</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,109</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; padding-left: 9pt; text-indent: -9pt">Accrued salaries, commissions and payroll taxes</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,573</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">4,492</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Litigation accruals</td> <td> </td> <td> </td> <td style="text-align: right">9</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">443</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Sales tax payable</td> <td> </td> <td> </td> <td style="text-align: right">1,123</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,353</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Legal and other professional fees</td> <td> </td> <td> </td> <td style="text-align: right">276</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">113</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Accounting fees</td> <td> </td> <td> </td> <td style="text-align: right">180</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt">Self-funded health insurance reserve</td> <td> </td> <td> </td> <td style="text-align: right">123</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">87</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt">Accrued interest and penalty</td> <td> </td> <td> </td> <td style="text-align: right">511</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">877</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">789</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">700</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Other Current Liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,584</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,185</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Summarized financial information concerning the Company's reportable segments is shown in the following table:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Medical Equipment</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Management of Diagnostic Imaging Centers</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the three months ended Dec. 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 46%; padding-left: 5.4pt">Net revenues from external customers</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,893</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">19,271</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">21,164</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(8</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">4,990</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4,982</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">65</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">977</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,042</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">70</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,728</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,798</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the three months ended Dec. 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Net revenues from external customers</td> <td> </td> <td>$</td> <td style="text-align: right">2,069</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">19,382</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">21,451</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">219</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(790</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">5,811</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5,021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">94</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">914</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,008</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">153</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,269</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Medical Equipment</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Management of Diagnostic Imaging Centers</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the six months ended Dec. 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 46%; padding-left: 5.4pt">Net revenues from external customers</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">3,874</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">38,270</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">42,144</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(569</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">9,701</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">9,132</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">132</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,878</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,010</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,143</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,233</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid; padding-left: 5.4pt">For the six months ended Dec. 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Net revenues from external customers</td> <td> </td> <td>$</td> <td style="text-align: right">4,352</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">38,845</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">43,197</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Inter-segment net revenues</td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">438</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">(Loss) Income from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(1,526</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">12,033</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10,507</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Depreciation and amortization</td> <td> </td> <td>$</td> <td style="text-align: right">185</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,818</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Capital expenditures</td> <td> </td> <td>$</td> <td style="text-align: right">1,754</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">2,964</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4,718</td> <td> </td></tr> </table>

6440000

6456000

6440000

6456000

383000

6465000

6447000

6465000

6447000

383000

0.99

0.87

0.93

0.82

0.23

0.26

0.48

0.45

0.12

0.13

128000

6896000 7262000 10218000 10982000 3322000 3720000 27438000 29808000 38501000 43298000 11063000 13490000 16172000 16373000 16172000 16373000 6000 72000 6000 72000 4313000 4171000 4828000 4686000 515000 515000

2528000

96000

752000

827000

853000

12041000

10330000

8406000

6930000

542000

404000

2689000

1912000

1084000

404000

5238000

5996000

966000

1335000

206000

276000

3543000

4112000

523000

273000

31818000

8904000

17505000

4301000

4480000

4599000

4877000

4960000

1351000

156000

287000

244000

6568000

6584000

383000

6593000

6575000

383000

0.92

0.80

0.23

0.26

0.44

0.12

0.13

90000

102000

1990000

1941000

4000

83000

4718000

2233000

90000

1754000

2143000

2964000

1798000

2269000

70000

153000

1728000

2116000

2003000

2010000

132000

185000

1878000

1818000

1042000

1008000

65000

94000

977000

914000

10507000

9132000

-569000

-1526000

9701000

12033000

4982000

5021000

-8000

-790000

4990000

5811000

438000

219000

43197000 42144000 3874000 4352000 38270000 38845000 21164000 21451000 1893000 2069000 19271000 19382000 0.242 0.458 0.3

6554000

6447000

146

383000

146

383000

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2020	Feb. 05, 2021
Entity Registrant Name	FONAR CORP
Entity Central Index Key	0000355019
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity File Number	0-10248
Entity Incorporation State Country Code	DE
Is Entity Interactive Data Current	Yes
Is Entity's Reporting Status Current?	Yes
Is Entity a Small Business	true
Entity Filer Category	Non-accelerated Filer
Is Entity an Emerging Growth Company	false
Trading Symbol	FONR
Security Exchange Name	NASDAQ
Security 12B Title	Common Stock
Entity Shell Company	false
Common Stock
Entity Common Stock, Shares Outstanding		6,554,210
Class B Common Stock
Entity Common Stock, Shares Outstanding		146
Class C Common Stock
Entity Common Stock, Shares Outstanding		382,513
Class A Common Stock
Entity Common Stock, Shares Outstanding		313,438

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Current Assets:
Cash and cash equivalents	$ 40,579	$ 36,802
Short term investments	32	32
Accounts receivable - net	4,171	4,313
Account receivable - related parties	72	6
Medical receivables -net	16,373	16,172
Management and other fees receivable -net	29,808	27,438
Management and other fees receivable - related medical practices -net	7,262	6,896
Inventories	1,844	1,649
Costs and estimated earnings in excess of billings on uncompleted contracts	153	153
Income taxes receivable		671
Prepaid expenses and other current assets	1,302	1,758
Total Current Assets	101,596	95,890
Accounts receivable	2,594	2,730
Deferred income tax asset	16,848	18,810
Property and equipment - net	21,683	21,364
Right-of-use Asset - operating lease	29,570	31,392
Right-of-use-asset - financing lease	1,226	1,326
Goodwill	3,985	3,985
Other intangible assets - net	4,014	4,109
Other assets	632	653
Total Assets	182,148	180,259
Current Liabilities:
Current portion of long-term debt and capital leases	222	108
Accounts payable	2,198	1,965
Other current liabilities	5,584	8,185
Unearned revenue on service contracts	4,029	4,105
Unearned revenue on service contracts - related parties	55
Operating lease liability - current portion	3,403	3,370
Financing lease liability - current portion	200	75
Customer deposits	1,232	855
Total Current Liabilities	16,923	18,663
Long-Term Liabilities:
Unearned revenue on service contracts	2,528	2,656
Deferred Income Tax Liability	234	234
Due to related party medical practices	93	93
Operating lease liability - net of current portion	28,415	30,105
Financing lease liability - net of current portion	1,151	1,251
Long-term debt and capital leases, less current portion	780	865
Other liabilities	148	150
Total Long-Term Liabilities	33,349	35,354
Total Liabilities	50,272	54,017
STOCKHOLDERS' EQUITY:
Paid-in capital in excess of par value	185,101	183,076
Accumulated deficit	(50,596)	(56,215)
Treasury stock, at cost	(675)	(675)
Total Fonar Corporation Stockholder Equity	133,831	126,187
Noncontrolling interests	(1,955)	55
Total Stockholders' Equity	131,876	126,242
Total Liabilities and Stockholders' Equity	182,148	180,259
Class A Non-Voting Preferred Stock
STOCKHOLDERS' EQUITY:
Preferred stock value
Preferred Stock
STOCKHOLDERS' EQUITY:
Preferred stock value
Common Stock
STOCKHOLDERS' EQUITY:
Common stock value	1	1
Class B Common Stock
STOCKHOLDERS' EQUITY:
Common stock value
Class C Common Stock
STOCKHOLDERS' EQUITY:
Common stock value

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Dec. 31, 2020	Jun. 30, 2020
Class A Non-Voting Preferred Stock
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Authorized	453,000	453,000
Preferred Stock, Issued	313,000	313,000
Preferred Stock, Outstanding	313,000	313,000
Preferred Stock
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Authorized	567,000	567,000
Preferred Stock, Issued
Preferred Stock, Outstanding
Common Stock
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	8,500,000	8,500,000
Common Stock, Issued	6,566,000	6,459,000
Common Stock, Outstanding	6,554,000	6,447,000
Class B Common Stock
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	227,000	227,000
Common Stock, Issued	146	146
Common Stock, Outstanding	146	146
Class C Common Stock
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Authorized	567,000	567,000
Common Stock, Issued	383,000	383,000
Common Stock, Outstanding	383,000	383,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
REVENUES
Patient fee revenue, net of contractual allowances and discounts	$ 5,238	$ 5,996	$ 10,330	$ 12,041
Product sales - net	3	3	31	195
Service and repair fees - net	1,862	2,038	3,788	4,102
Service and repair fees - related parties - net	28	28	55	55
Management and other fees - net	11,340	10,996	22,554	22,024
Management and other fees - related medical practices - net	2,693	2,390	5,386	4,780
Total Revenues - net	21,164	21,451	42,144	43,197
COSTS AND EXPENSES
Costs related to patient fee revenue	2,649	2,958	5,169	5,820
Costs related to product sales	192	120	325	450
Costs related to service and repair fees	608	772	1,234	1,522
Costs related to service and repair fees - related parties	9	10	18	20
Costs related to management and other fees	6,237	6,203	11,788	12,208
Costs related to management and other fees - related medical practices	1,522	1,621	2,950	3,157
Research and development	424	583	824	1,055
Selling, general and administrative	4,541	4,163	10,704	8,458
Total Costs and Expenses	16,182	16,430	33,012	32,690
INCOME
Income From Operations	4,982	5,021	9,132	10,507
Other Expenses			(140)
Interest Expense	(16)	(19)	(38)	(40)
Investment Income	75	139	187	287
Income Before Provision for Income Taxes and Noncontrolling Interests	5,041	5,141	9,141	10,754
Provision for Income Taxes	(1,113)	(932)	(1,962)	(2,039)
Net Income	3,928	4,209	7,179	8,715
Net Income - Noncontrolling Interests	(817)	(1,105)	(1,560)	(2,313)
Net Income - Attributable to FONAR	$ 3,111	$ 3,104	$ 5,619	$ 6,402
Basic Net Income Per Share	$ 0.48	$ 0.48	$ 0.87	$ 0.99
Weighted Average Basic Shares Outstanding	6,465	6,447	6,456	6,440
Common Stock
INCOME
Net Income - Attributable to FONAR	$ 2,923	$ 2,914	$ 5,281	$ 6,010
Basic Net Income Per Share	$ 0.45	$ 0.45	$ 0.82	$ 0.93
Diluted Net Income Per Share	$ 0.44	$ 0.44	$ 0.80	$ 0.92
Weighted Average Basic Shares Outstanding	6,465	6,447	6,456	6,440
Weighted Average Diluted Shares Outstanding	6,593	6,575	6,584	6,568
Class A Non-Voting Preferred Stock
INCOME
Net Income - Attributable to FONAR	$ 140	$ 142	$ 252	$ 292
Class C Common Stock
INCOME
Net Income - Attributable to FONAR	$ 48	$ 48	$ 86	$ 100
Basic Net Income Per Share	$ 0.12	$ 0.13	$ 0.23	$ 0.26
Diluted Net Income Per Share	0.12	0.13	0.23	0.26
Basic and Diluted Income Per Share	$ 0.12	$ 0.13	$ 0.23	$ 0.26
Weighted Average Basic Shares Outstanding	383	383	383	383
Weighted Average Diluted Shares Outstanding	383	383	383	383

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) $ in Thousands	Common Stock	Paid in capital in excess of par value	Accumulated Deficit	Treasury Stock	Non Controlling Interest	Total
Balance - Beginning, Value at Jun. 30, 2019	$ 1	$ 181,086	$ (64,455)	$ (675)	$ 2,156	$ 118,113
Issuance of common stock (value)		1,990				1,990
Net Income			6,402			6,402
Distributions - noncontrolling					(3,735)	(3,735)
Income - Noncontrolling interests					2,313	2,313
Balance - Ending, Value at Dec. 31, 2019	1	183,076	(58,053)	(675)	734	125,083
Balance - Beginning, Value at Sep. 30, 2019	1	183,076	(61,157)	(675)	1,609	122,854
Net Income			3,104			3,104
Distributions - noncontrolling					(1,980)	(1,980)
Income - Noncontrolling interests					1,105	1,105
Balance - Ending, Value at Dec. 31, 2019	1	183,076	(58,053)	(675)	734	125,083
Balance - Beginning, Value at Jun. 30, 2020	1	183,076	(56,215)	(675)	55	126,242
Issuance of common stock (value)		2,025				2,025
Net Income			5,619			5,619
Distributions - noncontrolling					(3,570)	(3,570)
Income - Noncontrolling interests					1,560	1,560
Balance - Ending, Value at Dec. 31, 2020	1	185,101	(50,596)	(675)	(1,955)	131,876
Balance - Beginning, Value at Sep. 30, 2020	1	183,076	(53,707)	(675)	(642)	128,053
Issuance of common stock (value)		2,025				2,025
Net Income			3,111			3,111
Distributions - noncontrolling					(2,130)	(2,130)
Income - Noncontrolling interests					817	817
Balance - Ending, Value at Dec. 31, 2020	$ 1	$ 185,101	$ (50,596)	$ (675)	$ (1,955)	$ 131,876

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities:
Net income	$ 7,179	$ 8,715
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,009	2,003
Amortization on right-of-use assets	1,922	1,656
Provision (Recovery) for bad debts	2,825	(978)
Deferred income tax - net	1,962	1,816
Compensatory element of stock issuances	83
Stock issued for costs and expense	1,941	1,990
Abandoned patents	1
(Increase) decrease in operating assets, net:
Accounts, medical and management fee receivable(s)	(5,549)	(4,300)
Notes receivable	25	11
Costs and estimated earnings in excess of billings on uncompleted contracts		372
Inventories	(195)	47
Income tax receivable	671
Prepaid expenses and other current assets	452	330
Other assets	(1)	(45)
Increase (decrease) in operating liabilities, net:
Accounts payable	233	(576)
Other current liabilities	(2,748)	430
Operating lease liabilities	(1,657)	(1,447)
Financing lease liabilities	24
Customer deposits	378	28
Billings in excess of costs and estimated earnings on uncompleted contracts		12
Other liabilities	(3)	123
Net cash provided by operating activities	9,552	10,187
Cash Flows from Investing Activities:
Purchases of property and equipment	(2,143)	(4,656)
Purchase of short term investment		(199)
Cost of patents	(90)	(62)
Net cash used in investing activities	(2,233)	(4,917)
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations	(35)	(24)
Proceeds from debt	63
Distributions to noncontrolling interests	(3,570)	(3,735)
Net cash used in financing activities	(3,542)	(3,759)
Net Increase in Cash and Cash Equivalents	3,777	1,511
Cash and Cash Equivalents - Beginning of Period	36,802	13,882
Cash and Cash Equivalents - End of Period	$ 40,579	$ 15,393

XML 17 R7.htm IDEA: XBRL DOCUMENT

NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

Basis of Presentation

XML 18 R8.htm IDEA: XBRL DOCUMENT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Revenues

Earnings Per Share

	Three months ended December 31, 2020						Three months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	3,111	$	2,923	$	48	$	3,104	$	2,914	$	48
Denominator:
Weighted average shares outstanding		6,465		6,465		383		6,447		6,447		383
Basic income per common share	$	0.48	$	0.45	$	0.12	$	0.48	$	0.45	$	0.13
Diluted
Denominator: Weighted average shares outstanding				6,465		383				6,447		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,593		383				6,575		383
Diluted income per common share			$	0.44	$	0.12			$	0.44	$	0.13

	Six months ended December 31, 2020						Six months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	5,619	$	5,281	$	86	$	6,402	$	6,010	$	100
Denominator:
Weighted average shares outstanding		6,456		6,456		383		6,440		6,440		383
Basic income per common share	$	0.87	$	0.82	$	0.23	$	0.99	$	0.93	$	0.26
Diluted
Denominator: Weighted average shares outstanding				6,456		383				6,440		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,584		383				6,568		383
Diluted income per common share			$	0.80	$	0.23			$	0.92	$	0.26

Recent Accounting Pronouncements

Reclassifications

XML 19 R9.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE

6 Months Ended

Dec. 31, 2020

Receivables [Abstract]

NOTE 3 - ACCOUNTS RECEIVABLE. MEDICAL RECEIVABLES AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $)

NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE

Receivables, net is comprised of the following at December 31, 2020, and June 30, 2020:

	December 31, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,686	$	515	$	4,171
Accounts receivable - related party	$	72		—	$	72
Medical receivable	$	16,373	$	—	$	16,373
Management and other fees receivable	$	43,298	$	13,490	$	29,808
Management and other fees receivable from related medical practices ("PC’s")	$	10,982	$	3,720	$	7,262

	June 30, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,828	$	515	$	4,313
Accounts receivable - related party	$	6		—	$	6
Medical receivable	$	16,172	$	—	$	16,172
Management and other fees receivable	$	38,501	$	11,063	$	27,438
Management and other fees receivable from related medical practices ("PC’s")	$	10,218	$	3,322	$	6,896

The Company's customers are concentrated in the healthcare industry.

Accounts Receivable

Long Term Accounts Receivable

2022	$	853
2023		827
2024		752
2025		96
Total	$	2,528

Medical Receivables

Management and Other Fees Receivable

The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2020 and 2019 are summarized in the following table.

	For the Three Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	966	$	1,335
Medicare/Medicaid		206		276
Workers' Compensation/Personal Injury		3,543		4,112
Other		523		273
Patient Fee Revenue, net of contractual allowances and discounts	$	5,238	$	5,996

	For the Six Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	1,912	$	2,689
Medicare/Medicaid		404		542
Workers' Compensation/Personal Injury		6,930		8,406
Other		1,084		404
Patient Fee Revenue, net of contractual allowances and discounts	$	10,330	$	12,041

XML 20 R10.htm IDEA: XBRL DOCUMENT

NOTE 4 - OPERATING & FINANCING LEASES

6 Months Ended

Dec. 31, 2020

Leases [Abstract]

NOTE 4 - OPERATING & FINANCING LEASES

NOTE 4 – OPERATING & FINANCING LEASES

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2020 is as follows:

Year Ending December 31,		Operating Lease Payments			Financing Lease Payments
	2021	$	4,960		$	244
	2022		4,877			244
	2023		4,599			244
	2024		4,480			244
	2025		4,301			244
	Thereafter		17,505			287
	Present value discount		(8,904	)		(156	)
	Total lease liability	$	31,818		$	1,351

XML 21 R11.htm IDEA: XBRL DOCUMENT

NOTE 5 - INVENTORIES

6 Months Ended

Dec. 31, 2020

Inventory Disclosure [Abstract]

NOTE 5 - INVENTORIES

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Purchased parts, components and supplies	$	1,614	$	1,544
Work-in-process		230		105
Total Inventories	$	1,844	$	1,649

XML 22 R12.htm IDEA: XBRL DOCUMENT

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

6 Months Ended

Dec. 31, 2020

Notes to Financial Statements

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS

Information relating to uncompleted contracts is as follows:

	December 31, 2020		June 30, 2020
Costs incurred on uncompleted contracts	$	448	$	448
Estimated earnings		309		309
Subtotal		757		757
Less: Billings to date		604		604
Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	153	$	153

XML 23 R13.htm IDEA: XBRL DOCUMENT

NOTE 7 - OTHER INTANGIBLE ASSETS

6 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

NOTE 7 - OTHER INTANGIBLE ASSETS

NOTE 7 – OTHER INTANGIBLE ASSETS

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Capitalized software development costs	$	7,005	$	7,005
Patents and copyrights		5,171		5,082
Non-compete		4,100		4,100
Customer relationships		3,800		3,800
Gross Other intangible assets		20,076		19,987
Less: Accumulated amortization		16,062		15,878
Other Intangible Assets	$	4,014	$	4,109

Amortization of patents and copyrights for the three months ended December 31, 2020 and 2019 amounted to $44 and $47, respectively.

Amortization of non-compete for the three months ended December 31, 2020 and 2019 amounted to $0 and $147, respectively.

Amortization of customer relationships for the three months ended December 31, 2020 and 2019 amounted to $47 and $47, respectively.

Amortization of patents and copyrights for the six months ended December 31, 2020 and 2019 amounted to $89 and $94, respectively.

Amortization of non-compete for the six months ended December 31, 2020 and 2019 amounted to $0 and $293, respectively.

Amortization of customer relationships for the six months ended December 31, 2020 and 2019 amounted to $95 and $95, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT

NOTE 8 - OTHER CURRENT LIABILITIES

6 Months Ended

Dec. 31, 2020

Other Liabilities, Current [Abstract]

NOTE 8 - OTHER CURRENT LIABILITIES

NOTE 8 – OTHER CURRENT LIABILITIES

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Accrued salaries, commissions and payroll taxes	$	2,573	$	4,492
Litigation accruals		9		443
Sales tax payable		1,123		1,353
Legal and other professional fees		276		113
Accounting fees		180		120
Self-funded health insurance reserve		123		87
Accrued interest and penalty		511		877
Other		789		700
Other Current Liabilities	$	5,584	$	8,185

XML 25 R15.htm IDEA: XBRL DOCUMENT

NOTE 9 - STOCKHOLDERS EQUITY

6 Months Ended

Dec. 31, 2020

STOCKHOLDERS' EQUITY:

NOTE 9 - STOCKHOLDERS EQUITY

NOTE 9 – STOCKHOLDERS EQUITY

Common Stock

During the six months ended December 31, 2019, the Company issued 90 shares of common stock for costs and expenses of $1,990.

XML 26 R16.htm IDEA: XBRL DOCUMENT

NOTE 10 - SEGMENT AND RELATED INFORMATION

6 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

NOTE 10 - SEGMENT AND RELATED INFORMATION

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.

Summarized financial information concerning the Company's reportable segments is shown in the following table:

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the three months ended Dec. 31, 2020
Net revenues from external customers	$	1,893		$	19,271	$	21,164
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(8	)	$	4,990	$	4,982
Depreciation and amortization	$	65		$	977	$	1,042
Capital expenditures	$	70		$	1,728	$	1,798

For the three months ended Dec. 31, 2019
Net revenues from external customers	$	2,069		$	19,382	$	21,451
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(790	)	$	5,811	$	5,021
Depreciation and amortization	$	94		$	914	$	1,008
Capital expenditures	$	153		$	2,116	$	2,269

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the six months ended Dec. 31, 2020
Net revenues from external customers	$	3,874		$	38,270	$	42,144
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(569	)	$	9,701	$	9,132
Depreciation and amortization	$	132		$	1,878	$	2,010
Capital expenditures	$	90		$	2,143	$	2,233

For the six months ended Dec. 31, 2019
Net revenues from external customers	$	4,352		$	38,845	$	43,197
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(1,526	)	$	12,033	$	10,507
Depreciation and amortization	$	185		$	1,818	$	2,003
Capital expenditures	$	1,754		$	2,964	$	4,718

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION

6 Months Ended

Dec. 31, 2020

Supplemental Cash Flow Elements [Abstract]

NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION

NOTE 11 – SUPPLEMENTAL CASH FLOW INFORMATION

During the six months ended December 31, 2020 and December 31, 2019, the Company paid $35 and $14 for interest, respectively.

During the six months ended December 31, 2020 and December 31, 2019, the Company paid $145 and $228 for income taxes, respectively.

XML 28 R18.htm IDEA: XBRL DOCUMENT

NOTE 12 - COMMITMENTS AND CONTINGENCIES

6 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

NOTE 12 - COMMITMENTS AND CONTINGENCIES

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Litigation

There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2020.

Other Matters

XML 29 R19.htm IDEA: XBRL DOCUMENT

NOTE 13 - INCOME TAXES

6 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

NOTE 13 - INCOME TAXES

A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

NOTE 14 - SUBSEQUENT EVENTS

6 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

NOTE 14 - SUBSEQUENT EVENTS

NOTE 14 – SUBSEQUENT EVENTS

The Company has evaluated events that occurred subsequent to December 31, 2020 and through the date the condensed consolidated financial statements were issued.

XML 31 R21.htm IDEA: XBRL DOCUMENT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Revenue

Revenues

Earnings Per Share

	Three months ended December 31, 2020						Three months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	3,111	$	2,923	$	48	$	3,104	$	2,914	$	48
Denominator:
Weighted average shares outstanding		6,465		6,465		383		6,447		6,447		383
Basic income per common share	$	0.48	$	0.45	$	0.12	$	0.48	$	0.45	$	0.13
Diluted
Denominator: Weighted average shares outstanding				6,465		383				6,447		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,593		383				6,575		383
Diluted income per common share			$	0.44	$	0.12			$	0.44	$	0.13

	Six months ended December 31, 2020						Six months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	5,619	$	5,281	$	86	$	6,402	$	6,010	$	100
Denominator:
Weighted average shares outstanding		6,456		6,456		383		6,440		6,440		383
Basic income per common share	$	0.87	$	0.82	$	0.23	$	0.99	$	0.93	$	0.26
Diluted
Denominator: Weighted average shares outstanding				6,456		383				6,440		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,584		383				6,568		383
Diluted income per common share			$	0.80	$	0.23			$	0.92	$	0.26

Recent Accounting Pronouncements

Reclassifications

XML 32 R22.htm IDEA: XBRL DOCUMENT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Earnings Per Share

	Three months ended December 31, 2020						Three months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	3,111	$	2,923	$	48	$	3,104	$	2,914	$	48
Denominator:
Weighted average shares outstanding		6,465		6,465		383		6,447		6,447		383
Basic income per common share	$	0.48	$	0.45	$	0.12	$	0.48	$	0.45	$	0.13
Diluted
Denominator: Weighted average shares outstanding				6,465		383				6,447		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,593		383				6,575		383
Diluted income per common share			$	0.44	$	0.12			$	0.44	$	0.13

	Six months ended December 31, 2020						Six months ended December 31, 2019
	Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
Basic
Numerator: Net income available to common stockholders	$	5,619	$	5,281	$	86	$	6,402	$	6,010	$	100
Denominator:
Weighted average shares outstanding		6,456		6,456		383		6,440		6,440		383
Basic income per common share	$	0.87	$	0.82	$	0.23	$	0.99	$	0.93	$	0.26
Diluted
Denominator: Weighted average shares outstanding				6,456		383				6,440		383
Convertible Class C Stock				128		—				128		—
Total Denominator for diluted earnings per share				6,584		383				6,568		383
Diluted income per common share			$	0.80	$	0.23			$	0.92	$	0.26

XML 33 R23.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)

6 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Summary of Allowance For Doubtful Accounts

Receivables, net is comprised of the following at December 31, 2020, and June 30, 2020:

	December 31, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,686	$	515	$	4,171
Accounts receivable - related party	$	72		—	$	72
Medical receivable	$	16,373	$	—	$	16,373
Management and other fees receivable	$	43,298	$	13,490	$	29,808
Management and other fees receivable from related medical practices ("PC’s")	$	10,982	$	3,720	$	7,262

	June 30, 2020
	Gross Receivable		Allowance for doubtful accounts		Net
Accounts receivable	$	4,828	$	515	$	4,313
Accounts receivable - related party	$	6		—	$	6
Medical receivable	$	16,172	$	—	$	16,172
Management and other fees receivable	$	38,501	$	11,063	$	27,438
Management and other fees receivable from related medical practices ("PC’s")	$	10,218	$	3,322	$	6,896

Receivables - Non Current - net

Future revenue to be recognized over the following four years as of December 31, 2020 is as follows:

2022	$	853
2023		827
2024		752
2025		96
Total	$	2,528

Patient fee revenue - net

The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2020 and 2019 are summarized in the following table.

	For the Three Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	966	$	1,335
Medicare/Medicaid		206		276
Workers' Compensation/Personal Injury		3,543		4,112
Other		523		273
Patient Fee Revenue, net of contractual allowances and discounts	$	5,238	$	5,996

	For the Six Months Ended December 31,
	2020		2019
Commercial Insurance/ Managed Care	$	1,912	$	2,689
Medicare/Medicaid		404		542
Workers' Compensation/Personal Injury		6,930		8,406
Other		1,084		404
Patient Fee Revenue, net of contractual allowances and discounts	$	10,330	$	12,041

XML 34 R24.htm IDEA: XBRL DOCUMENT

NOTE 4 - OPERATING & FINANCING LEASES (Tables)

6 Months Ended

Dec. 31, 2020

Leases [Abstract]

Lease, Liability, Maturity

A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2020 is as follows:

Year Ending December 31,		Operating Lease Payments			Financing Lease Payments
	2021	$	4,960		$	244
	2022		4,877			244
	2023		4,599			244
	2024		4,480			244
	2025		4,301			244
	Thereafter		17,505			287
	Present value discount		(8,904	)		(156	)
	Total lease liability	$	31,818		$	1,351

XML 35 R25.htm IDEA: XBRL DOCUMENT

NOTE 5 - INVENTORIES (Tables)

6 Months Ended

Dec. 31, 2020

Inventory Disclosure [Abstract]

Inventories

Inventories included in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Purchased parts, components and supplies	$	1,614	$	1,544
Work-in-process		230		105
Total Inventories	$	1,844	$	1,649

XML 36 R26.htm IDEA: XBRL DOCUMENT

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables)

6 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Information relating to uncompleted contracts

Information relating to uncompleted contracts is as follows:

	December 31, 2020		June 30, 2020
Costs incurred on uncompleted contracts	$	448	$	448
Estimated earnings		309		309
Subtotal		757		757
Less: Billings to date		604		604
Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	153	$	153

XML 37 R27.htm IDEA: XBRL DOCUMENT

NOTE 7 - OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Other intangible assets - net

Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Capitalized software development costs	$	7,005	$	7,005
Patents and copyrights		5,171		5,082
Non-compete		4,100		4,100
Customer relationships		3,800		3,800
Gross Other intangible assets		20,076		19,987
Less: Accumulated amortization		16,062		15,878
Other Intangible Assets	$	4,014	$	4,109

XML 38 R28.htm IDEA: XBRL DOCUMENT

NOTE 8 - OTHER CURRENT LIABILITIES (Tables)

6 Months Ended

Dec. 31, 2020

Other Liabilities, Current [Abstract]

Other current liabilities

Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:

	December 31, 2020		June 30, 2020
Accrued salaries, commissions and payroll taxes	$	2,573	$	4,492
Litigation accruals		9		443
Sales tax payable		1,123		1,353
Legal and other professional fees		276		113
Accounting fees		180		120
Self-funded health insurance reserve		123		87
Accrued interest and penalty		511		877
Other		789		700
Other Current Liabilities	$	5,584	$	8,185

XML 39 R29.htm IDEA: XBRL DOCUMENT

NOTE 10 - SEGMENT AND RELATED INFORMATION (Tables)

6 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Segment information

Summarized financial information concerning the Company's reportable segments is shown in the following table:

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the three months ended Dec. 31, 2020
Net revenues from external customers	$	1,893		$	19,271	$	21,164
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(8	)	$	4,990	$	4,982
Depreciation and amortization	$	65		$	977	$	1,042
Capital expenditures	$	70		$	1,728	$	1,798

For the three months ended Dec. 31, 2019
Net revenues from external customers	$	2,069		$	19,382	$	21,451
Inter-segment net revenues	$	219		$	—	$	219
(Loss) Income from operations	$	(790	)	$	5,811	$	5,021
Depreciation and amortization	$	94		$	914	$	1,008
Capital expenditures	$	153		$	2,116	$	2,269

	Medical Equipment			Management of Diagnostic Imaging Centers		Totals
For the six months ended Dec. 31, 2020
Net revenues from external customers	$	3,874		$	38,270	$	42,144
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(569	)	$	9,701	$	9,132
Depreciation and amortization	$	132		$	1,878	$	2,010
Capital expenditures	$	90		$	2,143	$	2,233

For the six months ended Dec. 31, 2019
Net revenues from external customers	$	4,352		$	38,845	$	43,197
Inter-segment net revenues	$	438		$	—	$	438
(Loss) Income from operations	$	(1,526	)	$	12,033	$	10,507
Depreciation and amortization	$	185		$	1,818	$	2,003
Capital expenditures	$	1,754		$	2,964	$	4,718

XML 40 R30.htm IDEA: XBRL DOCUMENT

NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - Health Diagnostics Management LLC (HDM)	Jul. 01, 2015
The ownership interest of Imperial Management Services after reorganization of newly expanded HDM (percent).	24.20%
The ownership interest of Health Management Corporation of America after reorganization of newly expanded HDM (percent).	45.80%
The ownership interest of the original investors of HDM after reorganization of newly expanded HDM (percent).	30.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Basic Numerator: Net income available to common stockholders	$ 3,111	$ 3,104	$ 5,619	$ 6,402
Basic Denominator: Weighted average shares outstanding	6,465	6,447	6,456	6,440
Basic income per common share	$ 0.48	$ 0.48	$ 0.87	$ 0.99
Shares included upon conversion of Class C Common to calculate a diluted EPS	128	128	128	128
Common Stock
Basic Numerator: Net income available to common stockholders	$ 2,923	$ 2,914	$ 5,281	$ 6,010
Basic Denominator: Weighted average shares outstanding	6,465	6,447	6,456	6,440
Basic income per common share	$ 0.45	$ 0.45	$ 0.82	$ 0.93
Shares included upon conversion of Class C Common to calculate a diluted EPS	128	128	128	128
Total Denominator for diluted earnings per share	6,593	6,575	6,584	6,568
Diluted income per common share	$ 0.44	$ 0.44	$ 0.80	$ 0.92
Class C Common Stock
Basic Numerator: Net income available to common stockholders	$ 48	$ 48	$ 86	$ 100
Basic Denominator: Weighted average shares outstanding	383	383	383	383
Basic income per common share	$ 0.12	$ 0.13	$ 0.23	$ 0.26
Shares included upon conversion of Class C Common to calculate a diluted EPS
Total Denominator for diluted earnings per share	383	383	383	383
Diluted income per common share	$ 0.12	$ 0.13	$ 0.23	$ 0.26

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Shares included upon conversion of Class C Common to calculate a diluted EPS.	128	128	128	128

XML 43 R33.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Accounts receivable	$ 4,171	$ 4,313
Accounts receivable - Related party	72	6
Medical Receivables	16,373	16,172
Management and other fees receivable	29,808	27,438
Management and other fees receivable from related medical practices ("PC's")	7,262	6,896
Gross Receivable
Accounts receivable	4,686	4,828
Accounts receivable - Related party	72	6
Medical Receivables	16,373	16,172
Management and other fees receivable	43,298	38,501
Management and other fees receivable from related medical practices ("PC's")	10,982	10,218
Allowance for Doubtful Accounts
Accounts receivable	515	515
Accounts receivable - Related party
Medical Receivables
Management and other fees receivable	13,490	11,063
Management and other fees receivable from related medical practices ("PC's")	$ 3,720	$ 3,322

XML 44 R34.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Receivables, Long-term Contracts or Programs [Abstract]
2022	$ 853
2023	827
2024	752
2025	96
Total	$ 2,528

XML 45 R35.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Patient fee revenue, net of contractual allowances and discounts	$ 5,238	$ 5,996	$ 10,330	$ 12,041
Commercial Insurance / Managed Care
Patient fee revenue, net of contractual allowances and discounts	966	1,335	1,912	2,689
Medicare/Medicaid
Patient fee revenue, net of contractual allowances and discounts	206	276	404	542
Workers Compensation/Personal Injury
Patient fee revenue, net of contractual allowances and discounts	3,543	4,112	6,930	8,406
Other
Patient fee revenue, net of contractual allowances and discounts	$ 523	$ 273	$ 1,084	$ 404

XML 46 R36.htm IDEA: XBRL DOCUMENT

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable -
Percentage of PC's net revenue derived from no-fault and personal injury protection claims	66.00%	60.00%	66.00%	63.00%
Percentage of consolidated net revenue from management fees charged to related party medical practices	12.70%	11.10%	12.80%	11.10%

XML 47 R37.htm IDEA: XBRL DOCUMENT

NOTE 4 - OPERATING & FINANCING LEASES (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Operating Lease Payments
2021	$ 4,960
2022	4,877
2023	4,599
2024	4,480
2025	4,301
Thereafter	17,505
Present Value discount	(8,904)
Total lease liability	31,818
Financing Lease Payments
2021	244
2022	244
2023	244
2024	244
2025	244
Thereafter	287
Present Value discount	(156)
Total lease liability	$ 1,351

XML 48 R38.htm IDEA: XBRL DOCUMENT

NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) $ in Thousands	6 Months Ended
	Dec. 31, 2020 USD ($)
Leases [Abstract]
Receivable from landlord for tenant improvements	$ 202
Operating lease payments	$ 33,300

XML 49 R39.htm IDEA: XBRL DOCUMENT

NOTE 5 - INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Inventory Disclosure [Abstract]
Purchased parts, components and supplies	$ 1,614	$ 1,544
Work-in-process	230	105
Total Inventories	$ 1,844	$ 1,649

XML 50 R40.htm IDEA: XBRL DOCUMENT

NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Notes to Financial Statements
Costs incurred on uncompleted contracts	$ 448	$ 448
Estimated earnings	309	309
Costs and estimated earnings on uncompleted contracts	757	757
Less: Billings to date	604	604
Total costs and estimated earnings in excess of billings on uncompleted contracts	$ 153	$ 153

XML 51 R41.htm IDEA: XBRL DOCUMENT

NOTE 7 - OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Gross other intangible assets	$ 20,076	$ 19,987
Less: Accumulated amortization	16,062	15,878
Other intangible assets-net	4,014	4,109
Capitalized software development costs
Gross other intangible assets	7,005	7,005
Patents and copyrights
Gross other intangible assets	5,171	5,082
Non-compete
Gross other intangible assets	4,100	4,100
Customer relationships
Gross other intangible assets	$ 3,800	$ 3,800

XML 52 R42.htm IDEA: XBRL DOCUMENT

NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Patents and copyrights
Amortization of intangible assets	$ 44	$ 47	$ 89	$ 94
Non-compete
Amortization of intangible assets	0	147	0	293
Customer relationships
Amortization of intangible assets	$ 47	$ 47	$ 95	$ 95

XML 53 R43.htm IDEA: XBRL DOCUMENT

NOTE 8 - OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Other Liabilities, Current [Abstract]
Accrued salaries, commissions and payroll taxes	$ 2,573	$ 4,492
Litigation accruals	9	443
Sales tax payable	1,123	1,353
Legal and other professional fees	276	113
Accounting fees	180	120
Self-funded health insurance reserve	123	87
Accrued interest and penalty	511	877
Other	789	700
Other current liabilities	$ 5,584	$ 8,185

XML 54 R44.htm IDEA: XBRL DOCUMENT

NOTE 9 - STOCKHOLDERS EQUITY (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS' EQUITY:
Stock issued for cost and expenses, shares	102	90
Stock issued for cost and expenses, value	$ 1,941	$ 1,990
Stock issued for compensation, shares	4
Stock issued for compensation, value	$ 83

XML 55 R45.htm IDEA: XBRL DOCUMENT

NOTE 10 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Net revenues from external customers	$ 21,164	$ 21,451	$ 42,144	$ 43,197
Inter-segment net revenues	219	219	438	438
(Loss) Income from operations	4,982	5,021	9,132	10,507
Depreciation and amortization	1,042	1,008	2,010	2,003
Capital expenditures	1,798	2,269	2,233	4,718
Medical Equipment
Net revenues from external customers	1,893	2,069	3,874	4,352
Inter-segment net revenues	219	219	438	438
(Loss) Income from operations	(8)	(790)	(569)	(1,526)
Depreciation and amortization	65	94	132	185
Capital expenditures	70	153	90	1,754
Management Of Diagnostic Imaging Centers
Net revenues from external customers	19,271	19,382	38,270	38,845
Inter-segment net revenues
(Loss) Income from operations	4,990	5,811	9,701	12,033
Depreciation and amortization	977	914	1,878	1,818
Capital expenditures	$ 1,728	$ 2,116	$ 2,143	$ 2,964

- Definition

Amount after tax of income (loss) from continuing operations attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 56 R46.htm IDEA: XBRL DOCUMENT

NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Interest paid	$ 35	$ 14
Income taxes paid	$ 145	$ 228

XML 57 R47.htm IDEA: XBRL DOCUMENT

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Litigation settelement description	In September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September 2020. The Company paid the remaining balance of $315 in September 2020.
Recorded tax obligations	$ 1,100
Tax interest and penalties	466
Maximum limit for individual claims under stop-loss umbrella policy for health insurance	110
Self-funded health insurance reserve	$ 123	$ 87

XML 58 R48.htm IDEA: XBRL DOCUMENT

NOTE 13 - INCOME TAXES (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,962	$ 2,039
Income tax component - current	0
Income tax component - deferred	1,962
Deferred tax assets	16,848
Deferred tax liability	234
Net operating loss (NOL) carryforwards available to offset future taxable income	$ 47,208
Reimbursement of alternative minimum tax credits description	The Company is allowing a full reimbursement of $1,342 of tax credits relating to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 135 317 1 false 24 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://fonar.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://fonar.com/role/BalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://fonar.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://fonar.com/role/StatementsOfIncome CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) Sheet http://fonar.com/role/CondensedConsolidatedStatementsOfChangesInEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://fonar.com/role/StatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentation NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Notes 9 false false R10.htm 00000010 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES Sheet http://fonar.com/role/Note4-OperatingFinancingLeases NOTE 4 - OPERATING & FINANCING LEASES Notes 10 false false R11.htm 00000011 - Disclosure - NOTE 5 - INVENTORIES Sheet http://fonar.com/role/Note5-Inventories NOTE 5 - INVENTORIES Notes 11 false false R12.htm 00000012 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS Notes 12 false false R13.htm 00000013 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS Sheet http://fonar.com/role/Note7-OtherIntangibleAssets NOTE 7 - OTHER INTANGIBLE ASSETS Notes 13 false false R14.htm 00000014 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES Sheet http://fonar.com/role/Note8-OtherCurrentLiabilities NOTE 8 - OTHER CURRENT LIABILITIES Notes 14 false false R15.htm 00000015 - Disclosure - NOTE 9 - STOCKHOLDERS EQUITY Sheet http://fonar.com/role/Note9-StockholdersEquity NOTE 9 - STOCKHOLDERS EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION Sheet http://fonar.com/role/Note10-SegmentAndRelatedInformation NOTE 10 - SEGMENT AND RELATED INFORMATION Notes 16 false false R17.htm 00000017 - Disclosure - NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://fonar.com/role/Note11-SupplementalCashFlowInformation NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION Notes 17 false false R18.htm 00000018 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES Sheet http://fonar.com/role/Note12-CommitmentsAndContingencies NOTE 12 - COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 00000019 - Disclosure - NOTE 13 - INCOME TAXES Sheet http://fonar.com/role/Note13-IncomeTaxes NOTE 13 - INCOME TAXES Notes 19 false false R20.htm 00000020 - Disclosure - NOTE 14 - SUBSEQUENT EVENTS Sheet http://fonar.com/role/Note14-SubsequentEvents NOTE 14 - SUBSEQUENT EVENTS Notes 20 false false R21.htm 00000021 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables) Tables http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable 23 false false R24.htm 00000024 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Tables) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesTables NOTE 4 - OPERATING & FINANCING LEASES (Tables) Tables http://fonar.com/role/Note4-OperatingFinancingLeases 24 false false R25.htm 00000025 - Disclosure - NOTE 5 - INVENTORIES (Tables) Sheet http://fonar.com/role/Note5-InventoriesTables NOTE 5 - INVENTORIES (Tables) Tables http://fonar.com/role/Note5-Inventories 25 false false R26.htm 00000026 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContractsTables NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables) Tables http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts 26 false false R27.htm 00000027 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsTables NOTE 7 - OTHER INTANGIBLE ASSETS (Tables) Tables http://fonar.com/role/Note7-OtherIntangibleAssets 27 false false R28.htm 00000028 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Tables) Sheet http://fonar.com/role/Note8-OtherCurrentLiabilitiesTables NOTE 8 - OTHER CURRENT LIABILITIES (Tables) Tables http://fonar.com/role/Note8-OtherCurrentLiabilities 28 false false R29.htm 00000029 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION (Tables) Sheet http://fonar.com/role/Note10-SegmentAndRelatedInformationTables NOTE 10 - SEGMENT AND RELATED INFORMATION (Tables) Tables http://fonar.com/role/Note10-SegmentAndRelatedInformation 29 false false R30.htm 00000030 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://fonar.com/role/Note1-DescriptionOfBusinessAndBasisOfPresentation 30 false false R31.htm 00000031 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPolicies-EarningsPerShareDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) Details 31 false false R32.htm 00000032 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarrative NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://fonar.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-ReceivablesNetDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net (Details) Details http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables 33 false false R34.htm 00000034 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableManagementOtherFeesReceivable-LongTermAccountsReceivableDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE & MANAGEMENT & OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) Details 34 false false R35.htm 00000035 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-PatientFeesRevenueDetails NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue (Details) Details 35 false false R36.htm 00000036 - Disclosure - NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) Sheet http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivable-DetailsNarrative NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative) Details http://fonar.com/role/Note3-AccountsReceivableMedicalReceivableAndManagementAndOtherFeesReceivableTables 36 false false R37.htm 00000037 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesDetails NOTE 4 - OPERATING & FINANCING LEASES (Details) Details http://fonar.com/role/Note4-OperatingFinancingLeasesTables 37 false false R38.htm 00000038 - Disclosure - NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) Sheet http://fonar.com/role/Note4-OperatingFinancingLeasesDetailsNarrative NOTE 4 - OPERATING & FINANCING LEASES (Details Narrative) Details http://fonar.com/role/Note4-OperatingFinancingLeasesTables 38 false false R39.htm 00000039 - Disclosure - NOTE 5 - INVENTORIES (Details) Sheet http://fonar.com/role/Note4-InventoriesDetails NOTE 5 - INVENTORIES (Details) Details http://fonar.com/role/Note5-InventoriesTables 39 false false R40.htm 00000040 - Disclosure - NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) Sheet http://fonar.com/role/Note6-CostsAndEstimatedEarningsOnUncompletedContracts-InformationRelatingToUncompletedContractsDetails NOTE 6 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts (Details) Details 40 false false R41.htm 00000041 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsDetails NOTE 7 - OTHER INTANGIBLE ASSETS (Details) Details http://fonar.com/role/Note7-OtherIntangibleAssetsTables 41 false false R42.htm 00000042 - Disclosure - NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) Sheet http://fonar.com/role/Note7-OtherIntangibleAssetsDetailsNarrative NOTE 7 - OTHER INTANGIBLE ASSETS (Details Narrative) Details http://fonar.com/role/Note7-OtherIntangibleAssetsTables 42 false false R43.htm 00000043 - Disclosure - NOTE 8 - OTHER CURRENT LIABILITIES (Details) Sheet http://fonar.com/role/Note8-OtherCurrentLiabilitiesDetails NOTE 8 - OTHER CURRENT LIABILITIES (Details) Details http://fonar.com/role/Note8-OtherCurrentLiabilitiesTables 43 false false R44.htm 00000044 - Disclosure - NOTE 9 - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://fonar.com/role/Note9-StockholdersEquityDetailsNarrative NOTE 9 - STOCKHOLDERS EQUITY (Details Narrative) Details http://fonar.com/role/Note9-StockholdersEquity 44 false false R45.htm 00000045 - Disclosure - NOTE 10 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) Sheet http://fonar.com/role/Note10-SegmentAndRelatedInformation-SegmentInformationDetails NOTE 10 - SEGMENT AND RELATED INFORMATION - Segment Information (Details) Details 45 false false R46.htm 00000046 - Disclosure - NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) Sheet http://fonar.com/role/Note11-SupplementalCashFlowInformationDetailsNarrative NOTE 11 - SUPPLEMENTAL CASH FLOW INFORMATION ($) (Details Narrative) Details http://fonar.com/role/Note11-SupplementalCashFlowInformation 46 false false R47.htm 00000047 - Disclosure - NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://fonar.com/role/Note12-CommitmentsAndContingenciesDetailsNarrative NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://fonar.com/role/Note12-CommitmentsAndContingencies 47 false false R48.htm 00000048 - Disclosure - NOTE 13 - INCOME TAXES (Details Narrative) Sheet http://fonar.com/role/Note13-IncomeTaxesDetailsNarrative NOTE 13 - INCOME TAXES (Details Narrative) Details http://fonar.com/role/Note13-IncomeTaxes 48 false false All Reports Book All Reports fonr-20201231.xml fonr-20201231.xsd fonr-20201231_cal.xml fonr-20201231_def.xml fonr-20201231_lab.xml fonr-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 64 0000355019-21-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000355019-21-000009-xbrl.zip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�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